

Christie M Ballantyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5473952/publications.pdf>

Version: 2024-02-01

1,028
papers

89,772
citations

384

134
h-index

515

267
g-index

1095
all docs

1095
docs citations

1095
times ranked

70033
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. <i>Journal of Cardiac Failure</i> , 2023, 29, 6-15.	0.7	2
2	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e53-e64.	0.8	15
3	Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. <i>Population Health Management</i> , 2022, 25, 39-45.	0.8	11
4	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 383-392.	2.1	15
5	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. <i>Stroke</i> , 2022, 53, 788-797.	1.0	88
6	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	1.0	78
7	Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. <i>American Journal of Medicine</i> , 2022, 135, 603-606.	0.6	11
8	Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100300.	1.3	4
9	Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. <i>Circulation</i> , 2022, 145, 259-267.	1.6	21
10	NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study. <i>Menopause</i> , 2022, 29, 309-316.	0.8	5
11	Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2022, 79, 220-222.	1.2	14
12	Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. <i>Diabetes Care</i> , 2022, 45, 372-380.	4.3	49
13	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. <i>American Journal of Human Genetics</i> , 2022, 109, 81-96.	2.6	24
14	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	1.6	27
15	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
16	Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, e021583.	1.6	10
17	An Open-label, Crossover Study Comparing EPA+DPA-Free Fatty Acids and EPA-Ethyl Esters in Adults with Elevated Triglycerides: ENHANCE-IT. <i>Journal of Clinical Lipidology</i> , 2022, 16, e14.	0.6	0
18	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	2.8	11

#	ARTICLE	IF	CITATIONS
19	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€™ PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	1.6	26
20	Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. <i>Diabetologia</i> , 2022, , 1.	2.9	7
21	Associations of Highâ€™Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT. <i>Journal of the American Heart Association</i> , 2022, 11, e023314.	1.6	3
22	A Headâ€™toâ€™Head Comparison of a Free Fatty Acid Formulation of Omegaâ€™3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCEâ€™ Study. <i>Journal of the American Heart Association</i> , 2022, 11, e024176.	1.6	5
23	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 286-297.	0.6	20
24	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCEâ€™. <i>Journal of the American Heart Association</i> , 2022, 11, e024999.	1.6	13
25	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. <i>Science Advances</i> , 2022, 8, eabl6579.	4.7	36
26	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. <i>Science Translational Medicine</i> , 2022, 14, eabj9625.	5.8	31
27	Sex and Race Differences in N-Terminal Proâ€™B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. <i>JAMA Cardiology</i> , 2022, 7, 623.	3.0	23
28	APOL1 Kidney Risk Variants and Proteomics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 684-692.	2.2	4
29	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) Tj ETQq1 1 0.784314 rgB2/Overlo	0.4	3
30	Obesity, Galectinâ€™3, and Incident Heart Failure: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023238.	1.6	8
31	Guideline-Concordant Statin Therapy Useâ€™in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1814-1817.	1.2	8
32	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Priorâ€™Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36
33	Exercise and Mortality in Heartâ€™Diseaseâ€™Cohorts. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1701-1703.	1.2	1
34	Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2022, 350, 82-89.	0.4	3
35	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. <i>Hypertension</i> , 2022, 79, 1984-1993.	1.3	17
36	Existing and emerging strategies to lower Lipoprotein(a). <i>Atherosclerosis</i> , 2022, 349, 110-122.	0.4	36

#	ARTICLE	IF	CITATIONS
37	Lipoprotein(a) and ethnicities. <i>Atherosclerosis</i> , 2022, 349, 42-52.	0.4	29
38	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. <i>Atherosclerosis Plus</i> , 2022, 49, 20-27.	0.3	4
39	Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr ^{-/-} Mice. <i>Cells</i> , 2022, 11, 1795.	1.8	4
40	Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	19
41	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2022, 16, 617-625.	0.6	15
42	Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2022, 68, 1084-1093.	1.5	3
43	Lowering LDL cholesterol in clinical practice: time for change?. <i>Lancet, The</i> , 2022, 400, 341-343.	6.3	3
44	Programmable Bio-NanoChip Technology for the Diagnosis of Cardiovascular Disease at the Point of Care. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 8, 6.	0.5	40
45	Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events. <i>JAMA Cardiology</i> , 2021, 6, 79-86.	3.0	20
46	Relation of Magnetic Resonance Imaging Based Arterial Signal Enhancement to Markers of Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2021, 140, 140-147.	0.7	4
47	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
48	High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 986-994.	1.3	11
49	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality. <i>JAMA Cardiology</i> , 2021, 6, 587.	3.0	35
50	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	1.4	23
51	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
52	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. <i>Clinical Chemistry</i> , 2021, 67, 143-153.	1.5	120
53	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2021, 77, 559-571.	1.2	31
54	Deficiency of Stat1 in CD11c+ Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet. <i>Diabetes</i> , 2021, 70, 720-732.	0.3	10

#	ARTICLE	IF	CITATIONS
55	Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. <i>Diabetes Care</i> , 2021, 44, e15-e17.	4.3	46
56	Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. <i>Population Health Management</i> , 2021, 24, 414-415.	0.8	1
57	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 533-538.	1.3	1
58	Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with premaTure Atherosclerosis) Registry7. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	3
59	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. <i>Human Molecular Genetics</i> , 2021, 30, 393-409.	1.4	32
60	Recreational substance use among patients with premature atherosclerotic cardiovascular disease. <i>Heart</i> , 2021, 107, 650-656.	1.2	37
61	Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Diseaseâ€”Perspective from the Veterans Affair Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	6
62	Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2021, 67, 653-661.	1.5	19
63	Has the â€”strengthâ€” of fish oil therapy been â€”reducedâ€”? Reconciling the results of REDUCE-IT and STRENGTH. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e7-e8.	1.4	10
64	Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1229-1238.	1.1	19
65	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
66	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	1.3	87
67	Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. <i>Nature Communications</i> , 2021, 12, 1927.	5.8	10
68	Abstract 57: Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT. <i>Stroke</i> , 2021, 52, .	1.0	2
69	Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100150.	1.3	9
70	Prevention: The past, present, and future of medicine and society. <i>Journal of Clinical Lipidology</i> , 2021, 15, 245-247.	0.6	3
71	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 215-223.	1.9	50
72	How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 28.	2.0	12

#	ARTICLE	IF	CITATIONS
73	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. <i>Nature Communications</i> , 2021, 12, 2182.	5.8	17
74	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	1.3	71
75	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2021, 146, 15-21.	0.7	8
76	Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. <i>Journal of the American Association of Nurse Practitioners</i> , 2021, 33, 967-974.	0.5	4
77	High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2021, 44, 1657-1663.	4.3	22
78	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
79	Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 793-800.	1.3	9
80	Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. <i>Nature Aging</i> , 2021, 1, 473-489.	5.3	69
81	CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation. <i>Immunology</i> , 2021, 164, 148-160.	2.0	7
82	Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2792-2795.	1.2	3
83	Six-year changes in N-terminal pro-brain natriuretic peptide and changes in weight and risk of obesity. <i>Obesity</i> , 2021, 29, 1215-1222.	1.5	1
84	The ARIC (Atherosclerosis Risk In Communities) Study. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2939-2959.	1.2	192
85	Statins and Your Memory. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3157-3159.	1.2	1
86	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383.	1.6	56
87	Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2021, 6, 782.	3.0	23
88	Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). <i>Journal of Clinical Lipidology</i> , 2021, 15, 649-652.	0.6	7
89	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrfEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021, 27, 1382-1392.	0.7	3
90	Association of Clonal Hematopoiesis With Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 42-52.	1.2	101

#	ARTICLE	IF	CITATIONS
91	Abstract 903: Circulating inflammatory proteins associated with mortality from causes other than the index cancer in older adult cancer survivors in the atherosclerosis risk in communities study. , 2021, , .		0
92	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. Current Cardiology Reports, 2021, 23, 116.	1.3	2
93	Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). American Journal of Cardiology, 2021, 158, 45-52.	0.7	5
94	Association Between Achieved ω -3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. JAMA Cardiology, 2021, 6, 910.	3.0	52
95	Proteins Associated with Risk of Kidney Function Decline in the General Population. Journal of the American Society of Nephrology: JASN, 2021, 32, 2291-2302.	3.0	23
96	Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. American Journal of Medicine, 2021, 134, 1047-1051.e2.	0.6	13
97	Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa - European Journal of Vascular Medicine, 2021, 50, 439-445.	0.6	3
98	Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genetics in Medicine, 2021, 23, 2404-2414.	1.1	14
99	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. Journal of the American Heart Association, 2021, 10, e020893.	1.6	9
100	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100997.	3.2	121
101	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. Journal of the American College of Cardiology, 2021, 78, 960-993.	1.2	146
102	Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Research and Care, 2021, 9, e002320.	1.2	8
103	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	3.0	86
104	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering. JAMA Cardiology, 2021, 6, 1397.	3.0	24
105	Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. Journal of the American College of Cardiology, 2021, 78, 1114-1123.	1.2	9
106	Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. Journal of the American Heart Association, 2021, 10, e020890.	1.6	10
107	Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007485.	0.9	14
108	Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin. Nature Communications, 2021, 12, 5296.	5.8	16

#	ARTICLE	IF	CITATIONS
109	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021, 15, 629-648.	0.6	69
110	Polygenic Risk Scores for Kidney Function and Their Associations with Circulating Proteome, and Incident Kidney Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3161-3173.	3.0	27
111	Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. <i>American Journal of Preventive Medicine</i> , 2021, 61, 492-500.	1.6	5
112	High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study. <i>Menopause</i> , 2021, 28, 284-291.	0.8	6
113	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1269-1279.	1.3	13
114	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2021, 67, 298-307.	1.5	4
115	Poststatin Lipid Therapeutics: A Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 32.	0.5	8
116	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537.	1.2	25
117	PCSK9-targeted therapies: present and future approaches. <i>Nature Reviews Cardiology</i> , 2021, 18, 805-806.	6.1	16
118	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	0.6	4
119	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100278.	1.3	14
120	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855.	1.6	39
121	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021, 144, 1750-1759.	1.6	36
122	Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 114-121.	1.2	1
123	Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, CIRCGEN121003460.	1.6	5
124	The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2019-2021.	1.2	1
125	Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020?. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 30-32.	0.8	1
126	Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities Study). <i>Circulation</i> , 2021, 144, 1845-1855.	0.7	7

#	ARTICLE	IF	CITATIONS
127	JCL Roundtable. Making prevention a priority. Journal of Clinical Lipidology, 2021, 15, 530-537.	0.6	2
128	Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD. Journal of Clinical Lipidology, 2021, 15, e1.	0.6	0
129	Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD. Circulation, 2021, 144, .	1.6	4
130	Abstract 9794: Factors Associated with Enhanced Low-Density Lipoprotein Cholesterol Lowering with Bempedoic Acid Among Patients Enrolled in Phase 3 Studies. Circulation, 2021, 144, .	1.6	0
131	Abstract 9797: Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome. Circulation, 2021, 144, .	1.6	0
132	Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male <i>Ldlr</i> ^{-/-} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 72-85.	1.1	20
133	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	1.0	9
134	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology, 2020, 27, 593-603.	0.8	224
135	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1030-1045.	1.8	19
136	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
137	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. American Heart Journal, 2020, 219, 70-77.	1.2	18
138	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. American Heart Journal, 2020, 221, 60-66.	1.2	5
139	Mortality Implications of Prediabetes and Diabetes in Older Adults. Diabetes Care, 2020, 43, 382-388.	4.3	52
140	Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4304-e4327.	1.8	19
141	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of Clinical Lipidology, 2020, 14, 649-659.e6.	0.6	70
142	Monocyte phenotyping and management of lipoprotein X syndrome. Journal of Clinical Lipidology, 2020, 14, 850-858.	0.6	4
143	APOL1 Risk Alleles, Cardiac Markers, and Risk of ESKD in African Americans: The Atherosclerosis Risk in Communities Study. Kidney Medicine, 2020, 2, 502-504.	1.0	1
144	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2020, 324, 2268.	3.8	540

#	ARTICLE	IF	CITATIONS
145	Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2020, 76, 781-793.	1.2	48
146	Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3798-e3807.	1.8	39
147	Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis. <i>JAMA Cardiology</i> , 2020, 5, 1144.	3.0	15
148	Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. <i>Journal of the American Heart Association</i> , 2020, 9, e015410.	1.6	14
149	Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2322-2331.	1.1	27
150	Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. <i>American Journal of Medicine</i> , 2020, 133, e508-e511.	0.6	31
151	High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. <i>Diabetes Care</i> , 2020, 43, e144-e146.	4.3	14
152	Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 745-754.	1.3	16
153	Zero Coronary Artery Calcium Score. <i>Circulation</i> , 2020, 142, 917-919.	1.6	23
154	Use of Lipid-Lowering Therapies in Patients with CKD and ASCVD: A 1-Year Update From GOULD—. <i>Journal of Clinical Lipidology</i> , 2020, 14, 603-604.	0.6	0
155	Physician Characteristics and Attitudes towards Lipid-Lowering Treatment and Variability in Implementation of Guidelines: Insights from the Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD) Reg. <i>Journal of Clinical Lipidology</i> , 2020, 14, 607-608.	0.6	0
156	Genetic Testing for Hypertriglyceridemia—Experience From a Single Center Lipid Clinic—. <i>Journal of Clinical Lipidology</i> , 2020, 14, 608-610.	0.6	0
157	Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2020, 3, e2011051.	2.8	33
158	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. <i>Nature Genetics</i> , 2020, 52, 969-983.	9.4	146
159	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	1.6	14
160	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100091.	1.3	2
161	Large-scale plasma proteomic analysis identifies proteins and biological pathways associated with incident dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e038307.	0.4	1
162	Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2020, 133, 1293-1301.e1.	0.6	33

#	ARTICLE	IF	CITATIONS
163	Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men. <i>BMJ Open</i> , 2020, 10, e034777.	0.8	4
164	Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014885.	1.6	11
165	Metabolic Inflammation and Insulin Resistance in Obesity. <i>Circulation Research</i> , 2020, 126, 1549-1564.	2.0	438
166	Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1296-1306.	0.6	3
167	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. <i>Current Atherosclerosis Reports</i> , 2020, 22, 25.	2.0	38
168	Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity. <i>Circulation</i> , 2020, 142, 657-669.	1.6	49
169	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. <i>Journal of Clinical Lipidology</i> , 2020, 14, 4-15.	0.6	3
170	Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. <i>Diabetes Care</i> , 2020, 43, 1200-1208.	4.3	25
171	Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2020, 9, e013560.	1.6	6
172	Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015405.	1.6	15
173	Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. <i>JACC: Case Reports</i> , 2020, 2, 1042-1045.	0.3	2
174	Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. <i>American Journal of Medicine</i> , 2020, 133, 1424-1432.e1.	0.6	22
175	Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database. <i>Diabetes Care</i> , 2020, 43, e58-e60.	4.3	3
176	The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk. <i>Circulation</i> , 2020, 141, 592-599.	1.6	124
177	Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure. <i>Circulation</i> , 2020, 141, 957-967.	1.6	33
178	Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 329.	3.8	103
179	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq1 1 0.784314 rBT /Ove	0.7	14
180	Dalceapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21

#	ARTICLE	IF	CITATIONS
181	Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?. <i>European Heart Journal</i> , 2020, 41, 3910-3912.	1.0	4
182	Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2020, 66, 686-696.	1.5	14
183	E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey. <i>Kansas Journal of Medicine</i> , 2020, 13, 318-321.	0.1	18
184	Abstract P194: Proteomic Analysis of Cardiac Troponin I And T in Older Adults Without Cardiovascular Disease. <i>Circulation</i> , 2020, 141, .	1.6	0
185	Abstract MP33: Association of Cardiac Troponin T and Troponin I With Peripheral Neuropathy in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2020, 141, .	1.6	0
186	PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?. <i>Transactions of the American Clinical and Climatological Association</i> , 2020, 131, 42-47.	0.9	0
187	Coronary artery disease in the young in the US population-based cohort. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 189-194.	0.5	6
188	Cardiovascular risk and complications associated with COVID-19. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 479-489.	0.5	10
189	Abstract 15265: Trace or Mild Valvular Heart Disease With Cardiac Remodeling, Damage, and Overload in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2020, 142, .	1.6	0
190	Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. <i>Angiology</i> , 2019, 70, 47-55.	0.8	18
191	Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. <i>Postgraduate Medicine</i> , 2019, 131, 390-396.	0.9	5
192	INTENSITY OF LIPID LOWERING THERAPY AMONG PATIENTS WITH POLYVASCULAR DISEASE: INSIGHTS FROM THE GOULD REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 241.	1.2	0
193	SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 911.	1.2	0
194	LIPID-LOWERING THERAPY IN DIFFERENT REGIONS OF THE UNITED STATES: INSIGHTS FROM GETTING TO AN IMPROVED UNDERSTANDING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND DYSLIPIDEMIA MANAGEMENT (GOULD): A REGISTRY OF HIGH CARDIOVASCULAR RISK PATIENTS IN THE UNITED STATES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1834.	1.2	0
195	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1159-1161.	1.2	79
196	Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). <i>American Journal of Cardiology</i> , 2019, 124, 696-701.	0.7	38
197	Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1795-1802.	1.3	14
198	Seven Metrics That Will Determine Your Cardiovascular Success or Failure. <i>JACC: Heart Failure</i> , 2019, 7, 648-650.	1.9	0

#	ARTICLE	IF	CITATIONS
199	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019, 74, 712-714.	1.2	21
200	High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2353-2361.	1.3	7
201	Lipoprotein(a) and Risk for Stroke and Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 67-69.	1.2	4
202	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	1.2	39
203	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49
204	Statin use in carnitine palmitoyltransferase II deficiency. <i>Journal of Clinical Lipidology</i> , 2019, 13, 550-553.	0.6	1
205	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. <i>Nature Communications</i> , 2019, 10, 5121.	5.8	62
206	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019, 4, 997.	3.0	38
207	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke. <i>Circulation Research</i> , 2019, 125, 773-782.	2.0	78
208	Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. <i>American Heart Journal</i> , 2019, 216, 62-73.	1.2	4
209	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1849-1850.	1.2	11
210	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019, 188, 1033-1054.	1.6	85
211	The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	14
212	Homozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registry. <i>Journal of Clinical Lipidology</i> , 2019, 13, e39.	0.6	0
213	Genetic Testing for Hypertriglyceridemia - Pilot Data from a Single Center Lipid Clinic. <i>Journal of Clinical Lipidology</i> , 2019, 13, e17-e18.	0.6	0
214	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 618-620.	1.6	96
215	Effects of Icosapent Ethyl on Total Ischemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
216	Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. <i>American Journal of Epidemiology</i> , 2019, 188, 2146-2155.	1.6	4

#	ARTICLE	IF	CITATIONS
217	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. <i>American Journal of Medicine</i> , 2019, 132, e693-e700.	0.6	16
218	Letter by Wu and Ballantyne Regarding Article, "Protein Kinase C β via Activating Transcription Factor 2 β -Mediated CD36 Expression and Foam Cell Formation of Ly6C ^{hi} Cells Contributes to Atherosclerosis" <i>Circulation</i> , 2019, 139, 2077-2078.	1.6	0
219	Metabolomic Pattern Predicts Incident Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1475-1482.	1.1	65
220	Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study) <i>Journal of the American College of Cardiology</i> , 2019, 73, 1075-1083.	1.6	10
221	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
222	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
223	ApoB, small-dense LDL-C, Lp(a), LpPLA ₂ activity, and cognitive change. <i>Neurology</i> , 2019, 92, e2580-e2593.	1.5	19
224	High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. <i>Circulation</i> , 2019, 139, 2642-2653.	1.6	155
225	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , 2019, 124, 296-302.	0.7	1
226	Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. <i>Circulation</i> , 2019, 139, 1341-1343.	1.6	17
227	Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults. <i>PLoS ONE</i> , 2019, 14, e0212892.	1.1	16
228	Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. <i>Journal of Applied Laboratory Medicine</i> , 2019, 4, 30-39.	0.6	61
229	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , 2019, 380, 1022-1032.	13.9	529
230	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019, 51, 636-648.	9.4	112
231	Cancer Survivorship and Subclinical Myocardial Damage. <i>American Journal of Epidemiology</i> , 2019, 188, 2188-2195.	1.6	8
232	Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. <i>Cardiology and Therapy</i> , 2019, 8, 79-90.	1.1	14
233	Sleep apnea and galectin-3: possible sex-specific relationship. <i>Sleep and Breathing</i> , 2019, 23, 1107-1114.	0.9	8
234	The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. <i>Journal of Clinical Lipidology</i> , 2019, 13, 797-803.e1.	0.6	25

#	ARTICLE	IF	CITATIONS
235	Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study" Circulation, 2019, 140, e772-e773.	1.6	3
236	Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Scientific Reports, 2019, 9, 20168.	1.6	10
237	Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circulation: Cardiovascular Imaging, 2019, 12, e009535.	1.3	56
238	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease. , 2019, , 171-177.		0
239	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans. JAMA Cardiology, 2019, 4, 51.	3.0	38
240	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation, 2019, 139, 410-412.	1.6	12
241	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 2019, 380, 11-22.	13.9	2,153
242	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 280, 109-117.	0.4	40
243	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004817.	0.9	2
244	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2019, 282, 52-56.	0.4	44
245	Abstract P413: Association Between High Sensitivity Troponin T and N-Terminal Pro B-Type Natriuretic Peptide and Fall Risk in Older Adult Participants of the Atherosclerosis Risk in Communities Study (ARIC). Circulation, 2019, 139, .	1.6	0
246	Abstract P021: Cardiac Biomarkers, Electrolytes, and Anemia with Arrhythmias over Two Weeks in Chronic Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2019, 139, .	1.6	0
247	Abstract MP44: Association of High-Sensitivity Troponin With Peripheral Neuropathy in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2019, 139, .	1.6	0
248	Abstract MP47: Diabetes, Prediabetes, and Short-Term Cardiovascular Risk and Death in Older Adults. Circulation, 2019, 139, .	1.6	0
249	Abstract P036: Association Between Circulating Galectin-3 and Arterial Stiffness in the Atherosclerosis Risk in Communities Study. Circulation, 2019, 139, .	1.6	0
250	Improving Outcomes After Myocardial Infarction in the US Population. Journal of the American Heart Association, 2018, 7, .	1.6	10
251	Bempedoic Acid (ETC-1002). Cardiology Clinics, 2018, 36, 257-264.	0.9	39
252	Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vascular Medicine, 2018, 23, 232-240.	0.8	46

#	ARTICLE	IF	CITATIONS
253	Low Density Lipoprotein Triglyceride and Incident Cardiovascular: Insights from the Atherosclerosis Risk in Communities Study*. <i>Journal of Clinical Lipidology</i> , 2018, 12, 527-528.	0.6	0
254	Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). <i>Journal of the American College of Cardiology</i> , 2018, 71, 1077-1084.	1.0	10
255	Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure. <i>Circulation</i> , 2018, 137, 2142-2151.	1.6	46
256	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Trial. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1077-1084.	1.0	10
257	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018, 3, 200.	3.0	41
258	Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2018, 121, 430-436.	0.7	12
259	SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. <i>American Journal of Preventive Medicine</i> , 2018, 54, 229-236.	1.6	14
260	Prevention of Heart Failure. <i>Circulation</i> , 2018, 137, 106-108.	1.6	9
261	Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. <i>American Heart Journal</i> , 2018, 197, 62-69.	1.2	6
262	Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2018, 274, 86-93.	0.4	20
263	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2018, 68, 26-33.	1.5	59
264	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2527-2536.	1.2	56
265	Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. <i>Journal of Women's Health</i> , 2018, 27, 1170-1176.	1.5	12
266	High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Heart Journal</i> , 2018, 39, 2412-2419.	1.0	46
267	Patient-specific flow descriptors and normalised wall index in peripheral artery disease: a preliminary study. <i>Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization</i> , 2018, 6, 119-127.	1.3	9
268	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
269	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , 2018, 21, 209-216.	0.8	30
270	Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. <i>Kidney International</i> , 2018, 93, 252-259.	2.6	53

#	ARTICLE	IF	CITATIONS
271	Association of midlife lipids with 20-year cognitive change: A cohort study. <i>Alzheimer's and Dementia</i> , 2018, 14, 167-177.	0.4	84
272	Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). <i>Atherosclerosis</i> , 2018, 268, 12-18.	0.4	13
273	Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2018, 268, 63-67.	0.4	24
274	Weight History and Subclinical Myocardial Damage. <i>Clinical Chemistry</i> , 2018, 64, 201-209.	1.5	16
275	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	6.3	628
276	Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1842-1850.	2.2	19
277	Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1940-1950.	1.8	17
278	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2012-2021.	1.2	95
279	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. <i>American Journal of Human Genetics</i> , 2018, 103, 691-706.	2.6	326
280	Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2018, 64, 1536-1537.	1.5	3
281	Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. <i>Current Atherosclerosis Reports</i> , 2018, 20, 35.	2.0	11
282	Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 156-169.	1.2	124
283	Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1141-1145.	0.6	10
284	Are All Benefits and Harms Equal?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 819-820.	1.2	1
285	Clinical Genetic Testing for Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2018, 72, 662-680.	1.2	387
286	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. <i>JAMA Cardiology</i> , 2018, 3, 806.	3.0	129
287	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥ 190 mg/dL. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004652.	0.9	43
288	Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	50

#	ARTICLE	IF	CITATIONS
289	Do Biomarkers Improve Short-term Risk Prediction of Global Cardiovascular Events in Older Adults? Insights from the Atherosclerosis Risk in Communities Study*. <i>Journal of Clinical Lipidology</i> , 2018, 12, 525-526.	0.6	0
290	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018, 39, 3499-3507.	1.0	375
291	Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2018, 138, 2326-2329.	1.6	10
292	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018, 41, 1281-1288.	0.7	151
293	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018, 277, 195-203.	0.4	298
294	Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the MetaboChip in the Population Architecture using Genomics and Epidemiology (PAGE) study. <i>Human Molecular Genetics</i> , 2018, 27, 2940-2953.	1.4	16
295	Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6786-6791.	3.3	68
296	Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	23
297	Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 39-45.	0.1	12
298	Abstract P168: The Association of Longitudinal Changes in Metabolic Syndrome With Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2018, 137, .	1.6	0
299	Abstract P048: Segment-Specific Pulse Wave Velocity and Subclinical Cardiac Overload and Damage in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2018, 137, .	1.6	0
300	Abstract MP17: Galectin-3 and Subsequent Risk of Lower-extremity Peripheral Artery Disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2018, 137, .	1.6	0
301	Abstract 598: Monounsaturated Fat Reduces Foamy Monocyte Formation and Atherosclerosis Development in Ldlr ^{-/-} Mice Compared to Western High Saturated Fat Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0
302	Abstract 562: Foamy Monocytes in Hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0
303	Abstract 17187: The Association of Longitudinal Patterns of Metabolic Syndrome With Elevated hs-cTnT: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2018, 138, .	1.6	0
304	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
305	Myocardial Injury, Obesity, and the Obesity Paradox. <i>JACC: Heart Failure</i> , 2017, 5, 56-63.	1.9	19
306	Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). <i>American Journal of Cardiology</i> , 2017, 119, 397-403.	0.7	14

#	ARTICLE	IF	CITATIONS
307	Serum vitamin D and change in lipid levels over 5 years: The Atherosclerosis Risk in Communities study. <i>Nutrition</i> , 2017, 38, 85-93.	1.1	26
308	Practical Approaches for Whole-Genome Sequence Analysis of Heart- and Blood-Related Traits. <i>American Journal of Human Genetics</i> , 2017, 100, 205-215.	2.6	50
309	Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. <i>Circulation</i> , 2017, 135, 720-723.	1.6	9
310	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 19.	1.3	19
311	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000335.	1.2	16
312	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 628-638.	0.8	17
313	Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. <i>JAMA Cardiology</i> , 2017, 2, 361.	3.0	88
314	From Plaque Burden to Plaque Composition. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 250-252.	2.3	3
315	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , 2017, 233, 61-66.	0.8	42
316	Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPAR γ . <i>Nature Communications</i> , 2017, 8, 14960.	5.8	46
317	Physical Activity, Obesity, and Subclinical Myocardial Damage. <i>JACC: Heart Failure</i> , 2017, 5, 377-384.	1.9	20
318	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
319	A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017, 120, 569-576.	0.7	11
320	The Upregulation of Integrin α _D β ₂ (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis. <i>Journal of Immunology</i> , 2017, 198, 4855-4867.	0.4	56
321	PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2017, 14, 385-386.	6.1	19
322	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition) Tj ETQq0 0 UqBT /Overlock 10 T		
323	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2017, 135, 2204-2206.	1.6	34
324	Lipoprotein (a) levels and Risk of Cardiovascular Disease Events in Diabetes Mellitus and Prediabetes: The Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 779-780.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Clinical Rheumatology</i> , 2017, 36, 2121-2128.	1.0	24
326	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
327	The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2017, 262, 131-137.	0.4	29
328	An <i>NPB</i> Promoter Polymorphism Associated With Elevated N-Terminal pro-BNP Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
329	ASSOCIATIONS OF LIPOPROTEIN(A) LEVELS WITH INCIDENT ATRIAL FIBRILLATION AND STROKE AMONG WHITES AND BLACKS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 485.	1.2	1
330	ASSOCIATION OF REMNANT-LIKE PARTICLE CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN TRIGLYCERIDE WITH INCIDENCE OF CARDIOVASCULAR EVENTS: THE ARIC STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1721.	1.2	1
331	DEVELOPMENT AND VALIDATION OF PREDICTION MODELS WITH NON-TRADITIONAL MARKERS FOR 10-YEAR RISK OF ISCHEMIC LEG AMPUTATION AMONG PERSONS WITH DIABETES: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2028.	1.2	0
332	Multimodality Strategy for Cardiovascular Risk Assessment. <i>Circulation</i> , 2017, 135, 2119-2132.	1.6	75
333	A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. <i>Journal of Clinical Lipidology</i> , 2017, 11, 596-599.	0.6	6
334	Rationale and design of <i>REDUCE-IT</i> : Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial. <i>Clinical Cardiology</i> , 2017, 40, 138-148.	0.7	154
335	High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2017, 40, 261-269.	4.3	25
336	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017, 267, 19-26.	0.4	64
337	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017, 49, 1758-1766.	9.4	470
338	Midlife systemic inflammatory markers are associated with late-life brain volume. <i>Neurology</i> , 2017, 89, 2262-2270.	1.5	97
339	Sedentary Behavior and Subclinical Cardiac Injury. <i>Circulation</i> , 2017, 136, 1451-1453.	1.6	9
340	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2017, 390, 1833-1842.	6.3	948
341	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
342	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1785-1822.	1.2	313

#	ARTICLE	IF	CITATIONS
343	Association of Elevated Triglycerides and Atherogenic Lipoproteins with Incident Cardiovascular Diseases: Insights from Genetic Data in the Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 788.	0.6	3
344	Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. <i>American Heart Journal</i> , 2017, 192, 19-25.	1.2	41
345	Association of High-Density Lipoprotein Cholesterol Versus Apolipoprotein A With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	13
346	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	39
347	Galectin-3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 223-230.	1.0	15
348	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. <i>Stroke</i> , 2017, 48, 3196-3202.	1.0	83
349	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017, 263, 137-144.	0.4	35
350	Pediatric Familial Hypercholesterolemia: Children and Adolescents Enrolled in the CASCADE Screening for Awareness. <i>Journal of Clinical Lipidology</i> , 2017, 11, 812-813.	0.6	3
351	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017, 119, 388-396.	0.7	12
352	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (<sc>AMG</sc> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 98-107.	2.2	60
353	Skeletal muscle inflammation and insulin resistance in obesity. <i>Journal of Clinical Investigation</i> , 2017, 127, 43-54.	3.9	436
354	Abstract P249: Hemostatic Factors and Long-Term Risk of Peripheral Arterial Disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2017, 135, .	1.6	0
355	Abstract P248: Glycemic Markers and Risk of Peripheral Artery Disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2017, 135, .	1.6	0
356	Abstract MP012: Plasma Galectin-3 Levels and Subsequent Risk of Incident Chronic Kidney Disease. <i>Circulation</i> , 2017, 135, .	1.6	0
357	Abstract P034: Comparison of the Prognostic Value of 1,5-anhydroglucitol (1,5-AG) and the Oral Glucose Tolerance Test (OGTT) in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2017, 135, .	1.6	0
358	Abstract 593: High-Monounsaturated Fat Mediterranean-Type Diet Reduces Foamy Monocyte Formation and Atherosclerosis in Ldlr ^{-/-} Mice on High-Cholesterol Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, .	1.1	0
359	Abstract 193: Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglyceride and Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study: Can Genetic Variants Provide New Insights on Triglycerides and Atherogenic Lipoproteins?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, .	1.1	0
360	Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 114-121.	0.5	3

#	ARTICLE	IF	CITATIONS
361	Abstract MP018: Performance of 1,5-anhydroglucitol Compared to the Oral Glucose Tolerance Test and Fasting Glucose for Identification of Diabetes in the Community. <i>Circulation</i> , 2017, 135, .	1.6	0
362	Abstract MP007: Higher Plasma Galectin-3 is Associated With Increased Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2017, 135, .	1.6	0
363	Abstract MP011: Cardiac Markers and Risk for Hospitalization with Infection: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2017, 135, .	1.6	0
364	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (<scp>ARIC</scp>) Study. <i>European Journal of Heart Failure</i> , 2016, 18, 629-637.	2.9	38
365	Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
366	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. <i>Journal of Medical Genetics</i> , 2016, 53, 835-845.	1.5	28
367	25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	9
368	P2-415: Association of Baseline Lipids with 20-Year Cognitive Change: The ARIC Neurocognitive Study. , 2016, 12, P804-P804.		0
369	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
370	Provider understanding of the 2013 ACC/AHA cholesterol guideline. <i>Journal of Clinical Lipidology</i> , 2016, 10, 497-504.e4.	0.6	61
371	Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids. <i>Journal of Clinical Lipidology</i> , 2016, 10, 700.	0.6	0
372	A dataset to assess providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Data in Brief</i> , 2016, 7, 595-598.	0.5	6
373	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1580.	3.8	420
374	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2016, 68, 92-125.	1.2	371
375	Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2118-2130.	1.2	227
376	Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1713-1722.	1.2	269
377	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 840-849.	5.5	159
378	Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. <i>American Heart Journal</i> , 2016, 181, 74-82.	1.2	58

#	ARTICLE	IF	CITATIONS
379	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. <i>Atherosclerosis</i> , 2016, 253, 81-87.	0.4	39
380	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1144-1149.	0.7	39
381	Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). <i>American Journal of Cardiology</i> , 2016, 118, 1399-1404.	0.7	6
382	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016, 182, 89-96.	1.2	15
383	Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. <i>Current Atherosclerosis Reports</i> , 2016, 18, 61.	2.0	78
384	Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. <i>Clinical Cardiology</i> , 2016, 39, 185-191.	0.7	43
385	Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4195-4204.	1.8	39
386	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1223-1229.	0.6	57
387	Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2016, 62, 1202-1210.	1.5	16
388	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	1.2	4
389	Severe Hypoglycemia and Elevated High-Sensitivity Cardiac Troponin T in Older Adults With Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1370-1371.	1.2	15
390	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. <i>Atherosclerosis</i> , 2016, 253, 156-163.	0.4	15
391	Obesity and Subtypes of Incident Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	149
392	Practice-Level Variation in Statin Use Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1368-1369.	1.2	45
393	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 125, 57-64.	1.0	37
394	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2373.	3.8	813
395	Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. <i>JAMA Cardiology</i> , 2016, 1, 519.	3.0	109
396	The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1529-1536.	0.8	5

#	ARTICLE	IF	CITATIONS
397	Defective Association of the Platelet Glycoprotein Ib-IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation. <i>Journal of Immunology</i> , 2016, 197, 288-295.	0.4	8
398	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. <i>American Journal of Cardiology</i> , 2016, 117, 1928-1933.	0.7	92
399	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. <i>Journal of Clinical Lipidology</i> , 2016, 10, 635-645.e1.	0.6	35
400	Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 71-78.	5.1	6
401	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. <i>Journal of Clinical Lipidology</i> , 2016, 10, 556-567.	0.6	119
402	Plaque Volume of Carotid Endarterectomy Specimens Measured by 3D Ultrasound Technology. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1118-1119.	2.3	2
403	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 240-249.	5.1	170
404	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	0.7	32
405	Genetic Testing in Hyperlipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 129-140.	1.2	4
406	The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. <i>American Journal of Epidemiology</i> , 2016, 183, 452-461.	1.6	31
407	Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease. <i>Expert Systems With Applications</i> , 2016, 54, 136-147.	4.4	33
408	Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Atherosclerosis</i> , 2016, 246, 115-120.	0.4	17
409	Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 1667-1681.	1.6	14
410	Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. <i>Clinical Biochemistry</i> , 2016, 49, 657-662.	0.8	28
411	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity. <i>Circulation</i> , 2016, 133, 631-638.	1.6	96
412	Lipoprotein(a) and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 88-89.	1.9	0
413	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016, 39, 677-685.	4.3	46
414	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 55-65.	1.0	82

#	ARTICLE	IF	CITATIONS
415	Abstract 52: Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	2
416	Abstract 138: Contemporary Patterns of Use of Antiplatelet Agents in Patients With Acute Myocardial Infarction: Insight From the National Cardiovascular Data Registry (NCDR). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, .	0.9	1
417	A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2016, 126, 3541-3555.	3.9	30
418	Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. <i>PLoS ONE</i> , 2016, 11, e0148765.	1.1	57
419	Abstract 253: The Association of Socioeconomic Status With Elevation of N-terminal Pro-b-type Natriuretic Peptide. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, .	0.9	0
420	Abstract 14: Statin Use Before and After the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, .	0.9	0
421	Abstract 664: Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Monocyte Phenotypes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	0
422	Abstract 623: Effect of High-intensity Statin Therapy on High-density Lipoprotein (HDL) Subfractions and Regression of Coronary Atheroma: The SATURN Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	0
423	Abstract P097: Shortness of Breath, Edema, and Fatigue and the Risk of Hospitalized Heart Failure (HF). The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2016, 133, .	1.6	0
424	Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. <i>Respiratory Research</i> , 2015, 16, 126.	1.4	2
425	Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. <i>Lipids in Health and Disease</i> , 2015, 14, 103.	1.2	10
426	Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. <i>American Heart Journal</i> , 2015, 170, 380-389.e4.	1.2	80
427	Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. <i>Diabetes Care</i> , 2015, 38, 1544-1550.	4.3	25
428	Genetic Testing in Hyperlipidemia. <i>Cardiology Clinics</i> , 2015, 33, 267-275.	0.9	7
429	Racial Differences in Circulating Natriuretic Peptide Levels: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	53
430	Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. <i>American Heart Journal</i> , 2015, 170, 961-967.	1.2	38
431	Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 464-471.	1.2	22
432	Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 77-83.	0.4	32

#	ARTICLE	IF	CITATIONS
433	sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 180-185.	1.2	22
434	Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 550-558.	2.1	16
435	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 111-121.	1.2	63
436	Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study. <i>Movement Disorders</i> , 2015, 30, 552-559.	2.2	113
437	Plasma Lactate and Incident Hypertension in the Atherosclerosis Risk in Communities Study. <i>American Journal of Hypertension</i> , 2015, 28, 216-224.	1.0	43
438	The World and Lipidology as It Relates to Cardiology. <i>Cardiology Clinics</i> , 2015, 33, xiii-xiv.	0.9	0
439	Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry. <i>Journal of Clinical Lipidology</i> , 2015, 9, 451-452.	0.6	0
440	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. <i>Atherosclerosis</i> , 2015, 241, 641-648.	0.4	16
441	Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence. <i>Circulation</i> , 2015, 132, 578-585.	1.6	92
442	High-Sensitivity Cardiac Troponin T and Risk of Hypertension. <i>Circulation</i> , 2015, 132, 825-833.	1.6	84
443	A common variant in the <i>CLDN7/ELP5</i> locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. <i>Physiological Genomics</i> , 2015, 47, 215-224.	1.0	10
444	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults. <i>Hypertension</i> , 2015, 66, 474-480.	1.3	11
445	Foamy Monocytes Form Early and Contribute to Nascent Atherosclerosis in Mice With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1787-1797.	1.1	71
446	Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. <i>American Journal of Medicine</i> , 2015, 128, 1253-1256.	0.6	10
447	Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2015, 115, 1212-1221.	0.7	153
448	FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 493-494.	2.3	70
449	The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial. <i>Atherosclerosis</i> , 2015, 240, 490-496.	0.4	63
450	The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 508.	2.0	0

#	ARTICLE	IF	CITATIONS
451	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509.	13.9	1,352
452	Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. <i>International Journal of Cardiology</i> , 2015, 187, 651-657.	0.8	36
453	Eligibility for Statin Therapy According to New Cholesterol Guidelines and Prevalent Use of Medication to Lower Lipid Levels in an Older US Cohort. <i>JAMA Internal Medicine</i> , 2015, 175, 138.	2.6	22
454	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. <i>American Journal of Cardiology</i> , 2015, 116, 481-484.	0.7	16
455	Recalibration of Blood Analytes over 25 Years in the Atherosclerosis Risk in Communities Study: Impact of Recalibration on Chronic Kidney Disease Prevalence and Incidence. <i>Clinical Chemistry</i> , 2015, 61, 938-947.	1.5	71
456	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015, , 39-55.	0.0	0
457	N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Hypertension</i> , 2015, 28, 1262-1266.	1.0	30
458	Postprandial effects on arterial stiffness parameters in healthy young adults. <i>Vascular Medicine</i> , 2015, 20, 501-508.	0.8	10
459	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort. <i>Circulation</i> , 2015, 132, 1329-1337.	1.6	137
460	Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 239-247.	0.5	21
461	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. <i>Circulation</i> , 2015, 132, 1979-1989.	1.6	54
462	Validity of self-report of lipid medication use: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2015, 242, 625-629.	0.4	5
463	Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. <i>Clinical Chemistry</i> , 2015, 61, 1524-1531.	1.5	34
464	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). <i>Journal of Clinical Lipidology</i> , 2015, 9, 377-383.	0.6	37
465	Provider Type and Quality of Outpatient Cardiovascular Disease Care. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1803-1812.	1.2	54
466	The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. <i>Journal of Hepatology</i> , 2015, 62, 841-847.	1.8	37
467	High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories. <i>Hypertension</i> , 2015, 65, 78-84.	1.3	35
468	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 21-26.	0.7	134

#	ARTICLE	IF	CITATIONS
469	Development of Chagas Cardiac Manifestations Among Texas Blood Donors. <i>American Journal of Cardiology</i> , 2015, 115, 113-117.	0.7	30
470	High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. <i>American Heart Journal</i> , 2015, 169, 31-38.e3.	1.2	59
471	Abstract P244: Combined Measures of Total and Abdominal Adiposity and the Likelihood of Subclinical Myocardial Damage. <i>Circulation</i> , 2015, 131, .	1.6	0
472	Abstract MP47: The Association of Socioeconomic Status with Subclinical Myocardial Damage. <i>Circulation</i> , 2015, 131, .	1.6	0
473	Abstract 11: Compliance With Risk Factor Optimization and Medical Therapy in Patients With Peripheral Vascular Disease (Peripheral Artery and Ischemic Cerebrovascular Disease) Compared to Ischemic Heart Disease.. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, .	0.9	0
474	Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation</i> , 2015, 132, .	1.6	1
475	Abstract 12446: Frequency and Practice Level Variation in Statin Use Among Patients With Diabetes: Insights From the NCDRA [®] PINNACLE Registry. <i>Circulation</i> , 2015, 132, .	1.6	0
476	Abstract 18914: Comparison of Statin Eligibility Using the Pooled Cohort Equations, ATP-III Framingham and Reynolds Risk Scores Among Adults Who Experienced ASCVD Events: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2015, 132, .	1.6	0
477	Abstract 276: Postprandial Effects on Monocyte Phenotype in Obese Humans With Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
478	Abstract 148: <i>Stat2</i> Deficiency Does Not Protect From Atherosclerosis in <i>Ldlr</i> Knockout Mice Fed a Western Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
479	Abstract 311: Comparative Effectiveness of Outpatient Cardiovascular Disease Care Delivery Between Physician and Non-Physician Primary Care Providers: Implications for Care Under the Affordable Care Act. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, .	0.9	0
480	Abstract 19227: Weight History Influences the Likelihood of Subclinical Myocardial Injury. <i>Circulation</i> , 2015, 132, .	1.6	0
481	Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy. <i>Circulation</i> , 2015, 132, .	1.6	4
482	Abstract 16992: Changes in Physical Activity and the Risk of Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2015, 132, .	1.6	0
483	Analysis of Multiple Association Studies Provides Evidence of an Expression QTL Hub in Gene-Gene Interaction Network Affecting HDL Cholesterol Levels. <i>PLoS ONE</i> , 2014, 9, e92469.	1.1	10
484	Low-Density Lipoprotein Electronegativity Is a Novel Cardiometabolic Risk Factor. <i>PLoS ONE</i> , 2014, 9, e107340.	1.1	23
485	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014, 5, 5068.	5.8	216
486	High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. <i>European Heart Journal</i> , 2014, 35, 1817-1824.	1.0	37

#	ARTICLE	IF	CITATIONS
487	Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. <i>European Heart Journal</i> , 2014, 35, 3277-3286.	1.0	214
488	Reply: The Association between Obstructive Sleep Apnea Severity and N-Terminal Pro-B-Type Natriuretic Peptide Levels in Women. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 869-870.	2.5	0
489	Comparative associations of diabetes risk factors with five measures of hyperglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000002.	1.2	21
490	Neck Circumference Is Not Associated With Subclinical Atherosclerosis in Retired National Football League Players. <i>Clinical Cardiology</i> , 2014, 37, 402-407.	0.7	20
491	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. <i>American Journal of Cardiology</i> , 2014, 114, 1836-1840.	0.7	11
492	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2434-2435.	1.2	0
493	Dual Role of the Leukocyte Integrin $\alpha 5 \beta 1$ in Angiogenesis. <i>Journal of Immunology</i> , 2014, 193, 4712-4721.	0.4	30
494	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. <i>Europace</i> , 2014, 16, 1426-1433.	0.7	144
495	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. <i>American Journal of Epidemiology</i> , 2014, 179, 621-632.	1.6	47
496	Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2743-2749.	1.2	83
497	Essential Role of CD11a in CD8 ⁺ T-Cell Accumulation and Activation in Adipose Tissue. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 34-43.	1.1	52
498	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 866-875.	0.8	18
499	Distribution of calcification in carotid endarterectomy tissues: Comparison of micro-computed tomography imaging with histology. <i>Vascular Medicine</i> , 2014, 19, 343-350.	0.8	9
500	Troponin T, NT-proBNP, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). <i>Vascular Medicine</i> , 2014, 19, 33-41.	0.8	16
501	Decrease the Incentives to Order Lipid Panels—Reply. <i>JAMA Internal Medicine</i> , 2014, 174, 473.	2.6	0
502	Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. <i>Atherosclerosis</i> , 2014, 232, 86-93.	0.4	40
503	Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies. <i>Journal of Clinical Lipidology</i> , 2014, 8, 313-314.	0.6	8
504	Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. <i>Atherosclerosis</i> , 2014, 234, 249-253.	0.4	10

#	ARTICLE	IF	CITATIONS
505	Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). <i>Clinical Biochemistry</i> , 2014, 47, 132-134.	0.8	17
506	ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure. <i>Journal of Clinical Lipidology</i> , 2014, 8, 350.	0.6	0
507	Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. <i>Atherosclerosis</i> , 2014, 233, 419-428.	0.4	78
508	Frequency and Practice-Level Variation in Inappropriate and Nonrecommended Prasugrel Prescribing. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2876-2877.	1.2	44
509	Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. <i>American Journal of Human Genetics</i> , 2014, 94, 233-245.	2.6	193
510	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. <i>New England Journal of Medicine</i> , 2014, 370, 1809-1819.	13.9	607
511	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	1.0	270
512	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 380-388.	0.5	139
513	Rationale and design of the familial hypercholesterolemia foundation CAscade SCReening for Awareness and DEtection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014, 167, 342-349.e17.	1.2	76
514	Inflammation versus Host Defense in Obesity. <i>Cell Metabolism</i> , 2014, 20, 708-709.	7.2	12
515	Obesity, Subclinical Myocardial Injury, and Incident Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 600-607.	1.9	81
516	Inactivating Mutations in <i>NPC1L1</i> and Protection from Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2072-2082.	13.9	386
517	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1069-1077.	1.1	386
518	Lipid lowering with PCSK9 inhibitors. <i>Nature Reviews Cardiology</i> , 2014, 11, 563-575.	6.1	207
519	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. <i>Journal of the American College of Cardiology</i> , 2014, 64, 196-206.	1.2	52
520	Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage. <i>Circulation</i> , 2014, 130, 1374-1382.	1.6	174
521	High Sensitivity Troponin T (Hs-TnT) Predicts Outcomes in Patients Admitted with Acute Decompensated Heart. <i>Journal of Cardiac Failure</i> , 2014, 20, S110.	0.7	0
522	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. <i>Atherosclerosis</i> , 2014, 236, 251-256.	0.4	8

#	ARTICLE	IF	CITATIONS
523	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. <i>Diabetes Care</i> , 2014, 37, 3114-3120.	4.3	50
524	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1013-1022.	2.3	54
525	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2465-2472.	1.1	41
526	Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. <i>Human Genetics</i> , 2014, 133, 985-995.	1.8	31
527	Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. <i>Human Genetics</i> , 2014, 133, 1105-1116.	1.8	16
528	Cardiac and Kidney Markers for Cardiovascular Prediction in Individuals With Chronic Kidney Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1770-1777.	1.1	57
529	ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies. <i>Journal of Clinical Lipidology</i> , 2014, 8, 339-340.	0.6	3
530	Association Between Low Density Lipoprotein Cholesterol or Low Density Lipoprotein Particle Concentration and Metabolic Syndrome and High Sensitivity C-Reactive Protein in Retired National Football League Players*. <i>Journal of Clinical Lipidology</i> , 2014, 8, 357-358.	0.6	0
531	Fiber Intake and Plasminogen Activator Inhibitor-1 in Type 2 Diabetes: Look AHEAD (Action for Health in) Tj ETQq1 1 0.784314 rgBT /C 114, 1800-1810.e2.	0.4	9
532	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	1.1	59
533	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1441-1448.	1.2	303
534	Lipoprotein Associated Phospholipase A2 Mass is Not Associated with Subclinical Coronary and Carotid Atherosclerosis in the Retired National Football League Players*. <i>Journal of Clinical Lipidology</i> , 2014, 8, 345-346.	0.6	0
535	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , 2014, 172, 239-241.	0.8	18
536	Association of Small Dense Low-Density Lipoprotein Cholesterol and Lipoprotein-Associated Phospholipase A2 with Carotid Plaque Characteristics in the Atherosclerosis Risk in Communities Study*. <i>Journal of Clinical Lipidology</i> , 2014, 8, 319-321.	0.6	0
537	Loss-of-Function Mutations in <i>APOC3</i> , Triglycerides, and Coronary Disease. <i>New England Journal of Medicine</i> , 2014, 371, 22-31.	13.9	936
538	Is High-Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low-to Moderate-Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <i>Clinical Cardiology</i> , 2014, 37, 653-659.	0.7	53
539	The Challenges of Genome-Wide Interaction Studies: Lessons to Learn from the Analysis of HDL Blood Levels. <i>PLoS ONE</i> , 2014, 9, e109290.	1.1	13
540	Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players. <i>Southern Medical Journal</i> , 2014, 107, 633-639.	0.3	16

#	ARTICLE	IF	CITATIONS
541	Integration of Biomarkers with Plaque Imaging. <i>Contemporary Cardiology</i> , 2014, , 203-214.	0.0	0
542	Abstract P021: NT-proBNP Predicts Incident Heart Failure Among Individuals in All BMI Categories. <i>Circulation</i> , 2014, 129, .	1.6	1
543	Abstract P018: Calibration of Analytes Over Twenty-Five Years in the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014, 129, .	1.6	3
544	Abstract MP13: N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2014, 129, .	1.6	0
545	Abstract 16: Diabetes, Pre-diabetes, and Progression of Subclinical Myocardial Damage. <i>Circulation</i> , 2014, 129, .	1.6	0
546	Abstract P010: Cardiac Risk Factors and 6-Year Change in high-sensitivity Cardiac Troponin-T.. <i>Circulation</i> , 2014, 129, .	1.6	0
547	Abstract MP87: Circulating sRAGE Levels And The Risk Of Heart Failure. <i>Circulation</i> , 2014, 129, .	1.6	0
548	Abstract 25: Six-year Change in C-reactive Protein Levels and Risk of Incident Diabetes, Cardiovascular Events and Mortality. <i>Circulation</i> , 2014, 129, .	1.6	0
549	Abstract 15: Frequency and Predictors of Inappropriate Aspirin Prescribing for Primary Prevention of Cardiovascular Disease: Insights from the NCDRA® PINNACLE Registry.. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, .	0.9	0
550	Abstract 19771: Persistent Thrombocytopenia after Myocardial Infarction is Associated with Increased Short- and Long-Term Mortality. <i>Circulation</i> , 2014, 130, .	1.6	0
551	Abstract 19852: The Relationship Between Obesity and Heart Failure is Stronger than Those for Other CVD Subtypes and Not Explained by Traditional Risk Factors. <i>Circulation</i> , 2014, 130, .	1.6	0
552	Abstract 12777: High Sensitivity Troponin T is Associated With Increased Heart Failure Risk in Metabolic Syndrome in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2014, 130, .	1.6	0
553	Abstract 16803: Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-Like Particle Cholesterol From the MARINE and ANCHOR Studies. <i>Circulation</i> , 2014, 130, .	1.6	0
554	Abstract 12693: Influence of Resting Heart Rate and Changes in Resting Heart Rate on Cardiovascular Outcomes From the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014, 130, .	1.6	0
555	Abstract 66: Small Dense LDL Cholesterol Predicts Incident Diabetes Mellitus: The Atherosclerosis Risk in Communities Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	1.1	0
556	Chronic inflammation role in the obesity-diabetes association: a case-cohort study. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 31.	1.2	88
557	Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 37-46.	1.0	119
558	A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. <i>Journal of Clinical Lipidology</i> , 2013, 7, 82-87.	0.6	21

#	ARTICLE	IF	CITATIONS
559	Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. <i>Annals of Epidemiology</i> , 2013, 23, 66-73.	0.9	72
560	The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). <i>Atherosclerosis</i> , 2013, 231, 371-377.	0.4	31
561	Comparison by Meta-Analysis of Mortality After Isolated Coronary Artery Bypass Grafting in Women Versus Men. <i>American Journal of Cardiology</i> , 2013, 112, 309-317.	0.7	87
562	Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. <i>International Journal of Cardiology</i> , 2013, 167, 180-184.	0.8	52
563	Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting Undertreatment of lipids in ACS) <i>Tj ETQq1 1007843144gBT /Ove</i>		
564	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013, 34, 1783-1789.	1.0	90
565	Coronary Artery Bypass Graft Surgery Remains the Standard of Care for Patients With Diabetes. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2013, 25, 97-99.	0.4	4
566	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 3741-3746.	0.8	52
567	Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk in The Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2013, 59, 1802-1810.	1.5	82
568	Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. <i>Cardiovascular Diabetology</i> , 2013, 12, 100.	2.7	60
569	Ultrasound in Cardiovascular Risk Prediction: Don't Forget the Plaque!. <i>Journal of the American Heart Association</i> , 2013, 2, e000180.	1.6	16
570	Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide, and Incidence of Stroke. <i>Stroke</i> , 2013, 44, 961-967.	1.0	145
571	Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study. <i>Thrombosis Research</i> , 2013, 132, 44-46.	0.8	2
572	Response to Zhou et al. Letter to the Editor: The effects of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. <i>Diabetes Research and Clinical Practice</i> , 2013, 99, e20.	1.1	0
573	Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis. <i>American Journal of Cardiology</i> , 2013, 112, 1287-1292.	0.7	6
574	Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients With Persistent High Triglycerides (the ANCHOR Study). <i>Journal of Clinical Lipidology</i> , 2013, 7, 270-271.	0.6	3
575	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013, 7, 292-303.	0.6	15
576	The Editor's Roundtable: Hypertriglyceridemia. <i>American Journal of Cardiology</i> , 2013, 112, 1133-1141.	0.7	2

#	ARTICLE	IF	CITATIONS
577	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013, 7, 661-670.	0.6	19
578	Application of Speckle-Tracking in the Evaluation of Carotid Artery Function in Subjects with Hypertension and Diabetes. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 901-909.e1.	1.2	15
579	ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects. <i>Journal of Clinical Lipidology</i> , 2013, 7, 283.	0.6	0
580	Association between statins and infections after coronary artery bypass grafting. <i>International Journal of Cardiology</i> , 2013, 168, 117-120.	0.8	17
581	Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1154-1162.	1.2	150
582	sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. <i>Diabetes</i> , 2013, 62, 2116-2121.	0.3	146
583	CD11a Regulates Effector CD8 T Cell Differentiation and Central Memory Development in Response to Infection with <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2013, 81, 1140-1151.	1.0	42
584	Authors' Reply. <i>American Journal of Cardiology</i> , 2013, 111, 455-456.	0.7	0
585	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013, 34, 1818-1825.	1.0	61
586	Cardiovascular Biomarkers and Subclinical Brain Disease in the Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2013, 44, 1803-1808.	1.0	59
587	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <i>European Heart Journal</i> , 2013, 34, 3182-3190.	1.0	86
588	Sleep Apnea Is Associated with Subclinical Myocardial Injury in the Community. The ARIC-SHHS Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1460-1465.	2.5	77
589	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. <i>Journal of Lipid Research</i> , 2013, 54, 1980-1987.	2.0	7
590	Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained. <i>PLoS Genetics</i> , 2013, 9, e1003379.	1.5	112
591	Elevated High-Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Cardiovascular Events at Older Age. <i>American Journal of Epidemiology</i> , 2013, 178, 1076-1084.	1.6	31
592	Association of Genome-Wide Variation With Highly Sensitive Cardiac Troponin-T Levels in European Americans and Blacks. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 82-88.	5.1	24
593	Combined Association of Creatinine, Albuminuria, and Cystatin C with All-Cause Mortality and Cardiovascular and Kidney Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 434-442.	2.2	36
594	Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2013, 36, 70-76.	4.3	38

#	ARTICLE	IF	CITATIONS
595	The Association of Plasma Lactate With Incident Cardiovascular Outcomes. <i>American Journal of Epidemiology</i> , 2013, 178, 401-409.	1.6	33
596	NH 2 -Terminal Pro-Brain Natriuretic Peptide and Risk of Diabetes. <i>Diabetes</i> , 2013, 62, 3189-3193.	0.3	86
597	Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus?. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 391-399.	5.1	30
598	Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study. <i>Obesity</i> , 2013, 21, 944-950.	1.5	51
599	Association Between Preoperative Diuretic Use and In-hospital Outcomes After Cardiac Surgery. <i>Cardiovascular Therapeutics</i> , 2013, 31, 291-297.	1.1	12
600	Icosapent ethyl for the treatment of hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1409-1416.	0.9	16
601	Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3589-3598.	0.3	116
602	<i>APOE</i> Modulates the Correlation Between Triglycerides, Cholesterol, and CHD Through Pleiotropy, and Gene-by-Gene Interactions. <i>Genetics</i> , 2013, 195, 1397-1405.	1.2	24
603	Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study. <i>Circulation: Heart Failure</i> , 2013, 6, 936-943.	1.6	46
604	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. <i>Circulation</i> , 2013, 128, 2395-2403.	1.6	109
605	Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients. <i>Medicine and Science in Sports and Exercise</i> , 2013, 45, 1043-1050.	0.2	21
606	Correlates of Repeat Lipid Testing in Patients With Coronary Heart Disease. <i>JAMA Internal Medicine</i> , 2013, 173, 1439.	2.6	18
607	Retinol binding protein 4 and incident diabetes – the Atherosclerosis Risk in Communities Study (ARIC) Tj ETQq1 1 0.784314 rgBT / 0.3 17	0.3	17
608	Lactate and Risk of Incident Diabetes in a Case-Cohort of the Atherosclerosis Risk in Communities (ARIC) Study. <i>PLoS ONE</i> , 2013, 8, e55113.	1.1	53
609	Elevated Plasma SPARC Levels Are Associated with Insulin Resistance, Dyslipidemia, and Inflammation in Gestational Diabetes Mellitus. <i>PLoS ONE</i> , 2013, 8, e81615.	1.1	43
610	The Impact of Rapid Weight Loss on Oxidative Stress Markers and the Expression of the Metabolic Syndrome in Obese Individuals. <i>Journal of Obesity</i> , 2013, 2013, 1-10.	1.1	36
611	Abstract 79: Troponin T, NT-proBNP, and Incidence of Stroke: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Stroke</i> , 2013, 44, .	1.0	0
612	Abstract 020: NT-proBNP, hs-Troponin T and Incident Venous Thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2013, 127, .	1.6	1

#	ARTICLE	IF	CITATIONS
613	Abstract MP26: Highly Sensitive Cardiac Troponin T is Associated with Cognitive Function and Incidence of Dementia. <i>Circulation</i> , 2013, 127, .	1.6	0
614	Abstract MP27: Cardiovascular Biomarkers and MRI-defined Small Vessel Disease of the Brain in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2013, 127, .	1.6	0
615	Abstract MP11: Elevated High Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Coronary Heart Disease at Older Age - Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2013, 127, .	1.6	0
616	Abstract 18: The Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0
617	Abstract 155: Contribution of Foamy Monocytes to Nascent Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0
618	Abstract 265: Plasma Lactate and Incident Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Hypertension</i> , 2013, 62, .	1.3	0
619	Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A ₂ Mass and Activity at Baseline and After Rosuvastatin Therapy. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 676-685.	5.1	33
620	Response to Letter From Watanabe and Aizawa Regarding Article, "Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study," by Lopez et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, .	2.1	1
621	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. <i>PLoS Genetics</i> , 2012, 8, e1002607.	1.5	419
622	Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects. <i>Circulation</i> , 2012, 125, 241-249.	1.6	239
623	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. <i>Journal of Lipid Research</i> , 2012, 53, 556-560.	2.0	11
624	Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. <i>Journal of Lipid Research</i> , 2012, 53, 2726-2733.	2.0	33
625	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. <i>Journal of Lipid Research</i> , 2012, 53, 2425-2428.	2.0	14
626	Carotid Arterial Wall Characteristics Are Associated With Incident Ischemic Stroke But Not Coronary Heart Disease in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Stroke</i> , 2012, 43, 103-108.	1.0	103
627	Lipid-Related Markers and Cardiovascular Disease Prediction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2499-506.	3.8	352
628	Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. <i>European Heart Journal</i> , 2012, 33, 238-251.	1.0	89
629	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. <i>European Heart Journal</i> , 2012, 33, 183-190.	1.0	149
630	Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 155-162.	2.1	123

#	ARTICLE	IF	CITATIONS
631	Relation of Lipid Gene Scores to Longitudinal Trends in Lipid Levels and Incidence of Abnormal Lipid Levels Among Individuals of European Ancestry. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 73-80.	5.1	30
632	Racial Differences in Association of Elevated Interleukin-18 Levels With Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2012, 35, 1513-1518.	4.3	14
633	Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2839-2847.	0.4	40
634	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. <i>Survey of Anesthesiology</i> , 2012, 56, 141-142.	0.1	15
635	Chromosome 9p21 Single Nucleotide Polymorphisms Are Not Associated With Recurrent Myocardial Infarction in Patients With Established Coronary Artery Disease. <i>Circulation Journal</i> , 2012, 76, 950-956.	0.7	24
636	Combined Association of Albuminuria and Cystatin C-Based Estimated GFR With Mortality, Coronary Heart Disease, and Heart Failure Outcomes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2012, 60, 207-216.	2.1	80
637	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
638	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	1.3	14
639	The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2012, 222, 135-137.	0.4	14
640	Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. <i>Atherosclerosis</i> , 2012, 222, 551-556.	0.4	19
641	A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. <i>Atherosclerosis</i> , 2012, 223, 421-426.	0.4	69
642	ApoE and the role of very low density lipoproteins in adipose tissue inflammation. <i>Atherosclerosis</i> , 2012, 223, 342-349.	0.4	23
643	Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. <i>Journal of Clinical Lipidology</i> , 2012, 6, 50-57.	0.6	14
644	Effects of coadministered extended-release niacin/laropirant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 235-243.	0.6	11
645	Clinical use of genetic typing in human lipid disorders. <i>Journal of Clinical Lipidology</i> , 2012, 6, 199-207.	0.6	3
646	Statin Therapy Alters the Relationship Between Apolipoprotein B and Both LDL-C and Non-HDL-C in High-Risk Patients: Effect of Race/Ethnic Background. <i>Journal of Clinical Lipidology</i> , 2012, 6, 272-273.	0.6	0
647	The Effect of Two Doses of AMR101 on Fasting Serum Triglycerides and Other Lipid Parameters in Statin-Treated Patients with Persistent High Triglycerides (≥ 200 and < 500 mg/dL): The ANCHOR Study. <i>Journal of Clinical Lipidology</i> , 2012, 6, 279-280.	0.6	1
648	Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk. <i>Journal of Clinical Lipidology</i> , 2012, 6, 290-291.	0.6	0

#	ARTICLE	IF	CITATIONS
649	Non-“high-density lipoprotein cholesterol reporting and goal attainment in primary care. <i>Journal of Clinical Lipidology</i> , 2012, 6, 545-552.	0.6	11
650	Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). <i>Journal of Clinical Lipidology</i> , 2012, 6, 565-572.	0.6	73
651	Developing and assessing cardiovascular biomarkers. <i>Translational Research</i> , 2012, 159, 265-276.	2.2	24
652	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. <i>American Heart Journal</i> , 2012, 163, 515-521.e3.	1.2	51
653	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	0.6	19
654	The effect of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, e6-e8.	1.1	19
655	Chronic Hyperglycemia and Subclinical Myocardial Injury. <i>Journal of the American College of Cardiology</i> , 2012, 59, 484-489.	1.2	116
656	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. <i>American Journal of Human Genetics</i> , 2012, 91, 823-838.	2.6	227
657	Outcomes of Preoperative Angiotensin-Converting Enzyme Inhibitor Therapy in Patients Undergoing Isolated Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2012, 110, 919-923.	0.7	35
658	Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). <i>American Journal of Cardiology</i> , 2012, 110, 984-992.	0.7	295
659	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study. <i>Journal of Obesity & Weight Loss Therapy</i> , 2012, 02, 1-8.	0.1	19
660	Prediction of Incident Heart Failure in General Practice. <i>Circulation: Heart Failure</i> , 2012, 5, 422-429.	1.6	185
661	ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 181-187.	1.3	80
662	Novel Markers of Kidney Function as Predictors of ESRD, Cardiovascular Disease, and Mortality in the General Population. <i>American Journal of Kidney Diseases</i> , 2012, 59, 653-662.	2.1	150
663	Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARE Project. <i>PLoS ONE</i> , 2012, 7, e36473.	1.1	46
664	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. <i>PLoS ONE</i> , 2012, 7, e50198.	1.1	40
665	Diabetes Medication Use and Blood Lactate Level among Participants with Type 2 Diabetes: The Atherosclerosis Risk in Communities Carotid MRI Study. <i>PLoS ONE</i> , 2012, 7, e51237.	1.1	15
666	Abstract P002: Evidence For Smoking Dependent Genetic Effects on C-reactive Protein Levels in a Multi-ethnic Cohort Setting: The Care Consortium.. <i>Circulation</i> , 2012, 125, .	1.6	0

#	ARTICLE	IF	CITATIONS
667	Abstract 051: Trans-ethnic Metabochip Genotyping of Established Lipid Loci Identifies Low Frequency Susceptibility Variants and Additional Independent Signals in Known Loci. <i>Circulation</i> , 2012, 125, .	1.6	0
668	Abstract MP074: High-sensitivity C-reactive Protein and Family History in the Prediction of Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2012, 125, .	1.6	0
669	Abstract P009: The Association of Liver Enzymes with Subclinical Myocardial Damage. <i>Circulation</i> , 2012, 125, .	1.6	0
670	Abstract P220: The Effect of Diet-Induced Weight Loss on HDL Functionality in Individuals with Metabolic Syndrome: Investigating Alteration of the Initial Step in Reverse Cholesterol Transport as a Function of Plasma Lipoprotein Composition. <i>Circulation</i> , 2012, 125, .	1.6	0
671	Abstract 303: Pre-operative Angiotensin Converting Enzyme Inhibitor use and outcomes in patients undergoing Isolated Coronary Artery Bypass Grafting. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, .	0.9	0
672	Abstract 304: The Outcomes of Pre-Procedural Angiotensin Converting Enzyme Inhibitor Therapy in patients undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, .	0.9	0
673	Abstract 453: Ceruloplasmin and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, .	1.1	0
674	Abstract 166: Small Dense LDL Cholesterol Is Associated with Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, .	1.1	0
675	Abstract 138: Deficiency of CD11a Reduces CD8+ T-Cell Activation and Proliferation in Adipose Tissue of Obese Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, .	1.1	0
676	Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels. <i>Circulation</i> , 2011, 123, 731-738.	1.6	461
677	Triglycerides and Cardiovascular Disease. <i>Circulation</i> , 2011, 123, 2292-2333.	1.6	1,511
678	Segmental Analysis of Carotid Arterial Strain Using Speckle-Tracking. <i>Journal of the American Society of Echocardiography</i> , 2011, 24, 1276-1284.e5.	1.2	27
679	Real-Time Co-Registration Using Novel Ultrasound Technology: Ex Vivo Validation and In Vivo Applications. <i>Journal of the American Society of Echocardiography</i> , 2011, 24, 720-728.	1.2	12
680	Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1111-1119.	1.2	161
681	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	0.6	483
682	Lipid Target Attainment by Switching Statin Monotherapy to Fenofibric Acid + Statin in Patients with Mixed Dyslipidemia and at High-/Highest-Risk for Coronary Heart Disease. <i>Journal of Clinical Lipidology</i> , 2011, 5, 202-203.	0.6	1
683	Barriers to Non-HDL-Cholesterol Goal Attainment: Exploring the Gaps in Knowledge, Attitude, and Practices of Providers*. <i>Journal of Clinical Lipidology</i> , 2011, 5, 211-213.	0.6	0
684	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S9-S17.	0.6	292

#	ARTICLE	IF	CITATIONS
685	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, S1-S8.	0.6	406
686	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). <i>Journal of Clinical Lipidology</i> , 2011, 5, 474-482.	0.6	22
687	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). <i>Journal of Clinical Lipidology</i> , 2011, 5, 401-407.	0.6	3
688	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
689	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. <i>Nature Reviews Cardiology</i> , 2011, 8, 253-265.	6.1	90
690	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2078-2087.	13.9	731
691	Peripheral artery disease, biomarkers, and darapladib. <i>American Heart Journal</i> , 2011, 161, 972-978.	1.2	20
692	Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. <i>American Heart Journal</i> , 2011, 161, 1140-1146.	1.2	43
693	Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. <i>American Heart Journal</i> , 2011, 162, 725-732.e1.	1.2	50
694	Barriers to Non-HDL Cholesterol Goal Attainment by Providers. <i>American Journal of Medicine</i> , 2011, 124, 876-880.e2.	0.6	30
695	White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Annals of Epidemiology</i> , 2011, 21, 739-748.	0.9	50
696	Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. <i>Journal of Vascular Surgery</i> , 2011, 53, 668-675.	0.6	19
697	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Tj ETQq1 1 0.784314 rgBT /Overlock 1 Current Medical Research and Opinion, 2011, 27, 1119-1129.	0.9	43
698	Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity. <i>Atherosclerosis</i> , 2011, 219, 100-108.	0.4	30
699	Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) carotid MRI study. <i>Atherosclerosis</i> , 2011, 219, 596-602.	0.4	38
700	Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. <i>Atherosclerosis</i> , 2011, 219, 737-742.	0.4	44
701	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. <i>Lancet, The</i> , 2011, 378, 1547-1559.	6.3	479
702	Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. <i>Blood</i> , 2011, 117, 5224-5230.	0.6	45

#	ARTICLE	IF	CITATIONS
703	Isolated Coronary Artery Bypass Grafting in Obese Individuals - A Propensity Matched Analysis of Outcomes -. Circulation Journal, 2011, 75, 1378-1385.	0.7	31
704	Effect of the Cannabinoid Receptorâ€”1 Antagonist Rimonabant on Inflammation in Mice With Dietâ€”Induced Obesity. Obesity, 2011, 19, 505-513.	1.5	19
705	Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities. Magnetic Resonance Imaging, 2011, 29, 1065-1075.	1.0	26
706	The Editor's Roundtable: JUPITER Follow-Up. American Journal of Cardiology, 2011, 107, 1549-1557.	0.7	2
707	Usefulness of Single Nucleotide Polymorphism in Chromosome 4q25 to Predict In-Hospital and Long-Term Development of Atrial Fibrillation and Survival in Patients Undergoing Coronary Artery Bypass Grafting. American Journal of Cardiology, 2011, 107, 1504-1509.	0.7	39
708	Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an) Tj ETQq0 0 0 rgBT /Overlock 10 of 50 537		
709	Intramural coronary lipid injection induces atheromatous lesions expressing proinflammatory chemokines: implications for the development of a porcine model of atherosclerosis. Cardiovascular Revascularization Medicine, 2011, 12, 304-311.	0.3	11
710	Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides. Cardiovascular Drugs and Therapy, 2011, 25, 59-67.	1.3	15
711	Simultaneous bilateral magnetic resonance imaging of the femoral arteries in peripheral arterial disease patients. Journal of Magnetic Resonance Imaging, 2011, 34, 150-156.	1.9	6
712	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of "Heart Positive," a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
713	Update on therapies targeting HDL. Current Opinion in Lipidology, 2011, 22, 514-516.	1.2	1
714	Nontraditional Markers of Glycemia. Diabetes Care, 2011, 34, 960-967.	4.3	108
715	CD11c Controls Herpes Simplex Virus 1 Responses To Limit Virus Replication during Primary Infection. Journal of Virology, 2011, 85, 9945-9955.	1.5	20
716	Association of Variation at the <i>ABO</i> Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin. Circulation: Cardiovascular Genetics, 2011, 4, 681-686.	5.1	77
717	Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study. Circulation, 2011, 123, 1367-1376.	1.6	655
718	CD11c/CD18 Expression Is Upregulated on Blood Monocytes During Hypertriglyceridemia and Enhances Adhesion to Vascular Cell Adhesion Molecule-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 160-166.	1.1	139
719	Nutrition and metabolism - sphingolipids and branched chain amino acids. Current Opinion in Lipidology, 2011, 22, 503-504.	1.2	6
720	Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Carotid MRI Study. European Heart Journal, 2011, 32, 459-468.	1.0	55

#	ARTICLE	IF	CITATIONS
721	Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1689-1695.	1.1	46
722	Sources of Variability in Measurements of Cardiac Troponin T in a Community-Based Sample: The Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2011, 57, 891-897.	1.5	74
723	Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. <i>Nature Genetics</i> , 2011, 43, 940-947.	9.4	191
724	Racial Differences in Glycemic Markers: A Cross-sectional Analysis of Community-Based Data. <i>Annals of Internal Medicine</i> , 2011, 154, 303.	2.0	168
725	Rust and Rupture: Atherosclerosis. , 2011, , 89-97.		0
726	Abstract P162: Has LDL Cholesterol (LDL-C) and Non-HDL Cholesterol (Non-HDL-C) Goal Attainment Improved 7 Years After Adult Treatment Panel III (ATP III) Guidelines Were Published?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
727	Abstract P43: Frequency and Predictors of Low-Density Lipoprotein Cholesterol Control and Appropriate Response to Elevated LDL-C Levels in Patients with Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	0.9	0
728	Therapy and clinical trials: HDL-cholesterol and niacin therapy “ past, present, and future. <i>Current Opinion in Lipidology</i> , 2010, 21, 165-166.	1.2	4
729	Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. <i>Blood</i> , 2010, 115, 5289-5299.	0.6	113
730	Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. <i>Acta Diabetologica</i> , 2010, 47, 199-207.	1.2	6
731	Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy. <i>American Journal of Cardiology</i> , 2010, 105, 1409-1412.	0.7	22
732	The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC Study. <i>BMC Endocrine Disorders</i> , 2010, 10, 9.	0.9	10
733	Biological, clinical and population relevance of 95 loci for blood lipids. <i>Nature</i> , 2010, 466, 707-713.	13.7	3,249
734	A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change. <i>Diabetes Care</i> , 2010, 33, 2297-2303.	4.3	92
735	Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. <i>Human Molecular Genetics</i> , 2010, 19, 1863-1872.	1.4	233
736	CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 186-192.	1.1	123
737	Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1647-1655.	0.9	176
738	Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 398-404.	1.3	21

#	ARTICLE	IF	CITATIONS
739	Marine ω -3 Fatty Acid Intake. <i>Diabetes Care</i> , 2010, 33, 197-199.	4.3	24
740	Association of Circulating Matrix Metalloproteinases With Carotid Artery Characteristics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1034-1042.	1.1	38
741	Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. <i>Vascular Medicine</i> , 2010, 15, 171-179.	0.8	30
742	METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. <i>Physician and Sportsmedicine</i> , 2010, 38, 180-182.	1.0	2
743	Intercellular Adhesion Molecule-1 G241R Polymorphism Predicts Risk of Incident Ischemic Stroke. <i>Stroke</i> , 2010, 41, 1038-1040.	1.0	18
744	High-Molecular-Weight Adiponectin and the Risk of Type 2 Diabetes in the ARIC Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5097-5104.	1.8	94
745	Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves Prediction of Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1600-1607.	1.2	794
746	Safety of extended-release niacin/laropiprant in patients with dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2010, 4, 105-112.e1.	0.6	30
747	Changes in Prescription Patterns for Ezetimibe/Simvastatin, Ezetimibe and Statin, and Statin Therapies and Expected Effects on LDL-C Reduction. <i>Journal of Clinical Lipidology</i> , 2010, 4, 219-220.	0.6	1
748	Management of Lp(a). <i>Journal of Clinical Lipidology</i> , 2010, 4, 240-247.	0.6	54
749	Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. <i>Journal of Clinical Lipidology</i> , 2010, 4, 365-370.	0.6	14
750	Preoperative Statin Therapy Decreases Risk of Postoperative Renal Insufficiency. <i>Cardiovascular Therapeutics</i> , 2010, 28, 80-86.	1.1	41
751	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. <i>Lancet, The</i> , 2010, 375, 1536-1544.	6.3	544
752	Impact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis. <i>EuroIntervention</i> , 2010, 5, 981-988.	1.4	10
753	Genetic Determinants of Plasma Von Willebrand Factor Antigen Levels: A Target Gene SNP and Haplotype Analysis of the ARIC Cohort. <i>Blood</i> , 2010, 116, 4310-4310.	0.6	0
754	Strategies for Optimizing Lipid Management. <i>Postgraduate Medicine</i> , 2010, 122, 13-20.	0.9	0
755	Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. <i>Thrombosis and Haemostasis</i> , 2009, 102, 179-180.	1.8	13
756	Advances in Lipid Testing and Management in Patients with Diabetes Mellitus. <i>Endocrine Practice</i> , 2009, 15, 641-652.	1.1	3

#	ARTICLE	IF	CITATIONS
757	â€œRisky Businessâ€• Circulation, 2009, 119, 362-364.	1.6	16
758	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Circulation, 2009, 120, e100-26.	1.6	25
759	Inflammation, Adipose Tissue, and T Cells: What Is the â€œStraight Skinnyâ€• on Lean Versus Fat Mice?. Circulation Research, 2009, 105, e3-4; author reply e5.	2.0	0
760	Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. Journal of Lipid Research, 2009, 50, 1685-1691.	2.0	80
761	Functional Role of CD11c ⁺ Monocytes in Atherogenesis Associated With Hypercholesterolemia. Circulation, 2009, 119, 2708-2717.	1.6	200
762	Lipoprotein-Associated Phospholipase A ₂ and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2009, 40, 376-381.	1.0	79
763	Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrology Dialysis Transplantation, 2009, 24, 2452-2457.	0.4	22
764	Inflammatory Protein Levels and Depression Screening After Coronary Stenting Predict Major Adverse Coronary Events. Biological Research for Nursing, 2009, 11, 163-173.	1.0	8
765	Criteria for Evaluation of Novel Markers of Cardiovascular Risk. Circulation, 2009, 119, 2408-2416.	1.6	998
766	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease. Clinical Chemistry, 2009, 55, 378-384.	1.5	405
767	Impact of Adding a Single Allele in the 9p21 Locus to Traditional Risk Factors on Reclassification of Coronary Heart Disease Risk and Implications for Lipid-Modifying Therapy in the Atherosclerosis Risk in Communities Study. Circulation: Cardiovascular Genetics, 2009, 2, 279-285.	5.1	91
768	Statin-Induced Diabetes: Will It Change Clinical Practice?. Diabetes Care, 2009, 32, 1941-1943.	4.3	8
769	Correlates of Carotid Plaque Presence and Composition as Measured by MRI. Circulation: Cardiovascular Imaging, 2009, 2, 314-322.	1.3	56
770	The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovascular Disorders, 2009, 9, 3.	0.7	34
771	Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. American Journal of Cardiology, 2009, 103, 369-374.	0.7	80
772	Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. American Journal of Cardiology, 2009, 103, 515-522.	0.7	60
773	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study). American Journal of Cardiology, 2009, 103, 1694-1702.	0.7	62
774	Improved Horvitzâ€™Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology. Statistics in Biosciences, 2009, 1, 32-49.	0.6	112

#	ARTICLE	IF	CITATIONS
775	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. <i>BMC Medical Genetics</i> , 2009, 10, 111.	2.1	43
776	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
777	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1336-1363.	1.2	50
778	Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2009, 54, 2388-2395.	1.2	49
779	Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2009, 3, 332-340.	0.6	64
780	Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2009, 3, 341-344.	0.6	2
781	Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Context-Specific Risk of Type 2 Diabetes in African American and Caucasian Adults: The Atherosclerosis Risk in Communities Study. <i>Diabetes</i> , 2009, 58, 285-289.	0.3	28
782	Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). <i>Platelets</i> , 2009, 20, 199-205.	1.1	13
783	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. <i>Metabolic Syndrome and Related Disorders</i> , 2009, 7, 601-610.	0.5	9
784	Using the Whole Cohort in the Analysis of Case-Cohort Data. <i>American Journal of Epidemiology</i> , 2009, 169, 1398-1405.	1.6	130
785	Development and Validation of a Patient Self-assessment Score for Diabetes Risk. <i>Annals of Internal Medicine</i> , 2009, 151, 775.	2.0	253
786	What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?. <i>Current Opinion in Lipidology</i> , 2009, 20, 467-476.	1.2	29
787	Emerging Assays. , 2009, , 178-183.		0
788	Monocyte integrin CD11c/CD18 is a functional biomarker for risk of cardiovascular disease. <i>FASEB Journal</i> , 2009, 23, 593.7.	0.2	0
789	Monocyte CD11c/CD18 expression is upregulated postprandially and mediates firm arrest on VCAMâ€1. <i>FASEB Journal</i> , 2009, 23, 640.5.	0.2	0
790	Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery?. <i>Texas Heart Institute Journal</i> , 2009, 36, 540-5.	0.1	18
791	Prevalence of Metabolic Syndrome and Associated Risk Factors in Asian Indians. <i>Journal of Immigrant and Minority Health</i> , 2008, 10, 313-323.	0.8	35
792	Increased Myocardial Susceptibility to Repetitive Ischemia With Highâ€fat dietâ€induced Obesit. <i>Obesity</i> , 2008, 16, 2593-2600.	1.5	31

#	ARTICLE	IF	CITATIONS
793	How to identify patients with vulnerable plaques. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 824-833.	2.2	7
794	Association of C-Reactive Protein and Microalbuminuria (from the National Health and Nutrition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	0.7	73
795	Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins. <i>American Journal of Cardiology</i> , 2008, 101, 490-496.	0.7	94
796	Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemiaâ€”A list of study investigators appears in the Appendix.. <i>American Journal of Cardiology</i> , 2008, 101, 625-630.	0.7	164
797	The Editorâ€™s Roundtable: Atherosclerosis Regression. <i>American Journal of Cardiology</i> , 2008, 101, 967-974.	0.7	7
798	Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Nonâ€™HDL Cholesterol (from the) Tj ETQq0 0 0 rgBT /Overlock 10	0.7	10
799	The Editor's Roundtable: Lipid Management Beyond Statinsâ€™Reducing Residual Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2008, 102, 559-567.	0.7	10
800	Does Preoperative Statin Therapy Improve Outcomes in Patients Undergoing Isolated Cardiac Valve Surgery?. <i>American Journal of Cardiology</i> , 2008, 102, 1235-1239.	0.7	23
801	The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1632-1641.	1.2	207
802	Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Nonâ€™High-Density Lipoprotein Cholesterol Targets in High-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2008, 52, 626-632.	1.2	99
803	A case report of myopathy from consumption of red yeast rice. <i>Journal of Clinical Lipidology</i> , 2008, 2, 60-62.	0.6	23
804	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008, 2, 91-105.	0.6	22
805	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. <i>Journal of Clinical Lipidology</i> , 2008, 2, 79-90.	0.6	37
806	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Nonâ€™HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008, 2, 436-446.	0.6	13
807	Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. <i>American Heart Journal</i> , 2008, 155, 541-546.	1.2	71
808	Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. <i>American Heart Journal</i> , 2008, 156, 719-727.	1.2	82
809	Relationship of Alcohol Consumption and Type of Alcoholic Beverage Consumed With Plasma Lipid Levels: Differences Between Whites and African Americans of the ARIC Study. <i>Annals of Epidemiology</i> , 2008, 18, 101-107.	0.9	66
810	Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) Gâ€™765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. <i>Atherosclerosis</i> , 2008, 196, 926-930.	0.4	50

#	ARTICLE	IF	CITATIONS
811	Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2008, 200, 322-328.	0.4	17
812	Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors. <i>Cardiology Clinics</i> , 2008, 26, 547-560.	0.9	28
813	Developmental Control of Integrin Expression Regulates Th2 Effector Homing. <i>Journal of Immunology</i> , 2008, 180, 4656-4667.	0.4	18
814	Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. <i>Circulation</i> , 2008, 117, 2458-2466.	1.6	186
815	Response to Letters Regarding Article, "Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden." <i>Circulation</i> , 2008, 118, .	1.6	0
816	Association of Lactate With Blood Pressure Before and After Rapid Weight Loss. <i>American Journal of Hypertension</i> , 2008, 21, 1337-1342.	1.0	29
817	APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. <i>Human Molecular Genetics</i> , 2008, 17, 2039-2046.	1.4	21
818	Del-1, an Endogenous Leukocyte-Endothelial Adhesion Inhibitor, Limits Inflammatory Cell Recruitment. <i>Science</i> , 2008, 322, 1101-1104.	6.0	271
819	Association of the Complement Factor H Y402H Polymorphism With Cardiovascular Disease Is Dependent Upon Hypertension Status: The ARIC Study. <i>American Journal of Hypertension</i> , 2008, 21, 533-538.	1.0	29
820	Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. <i>Blood</i> , 2008, 111, 3607-3614.	0.6	52
821	Expression, activation, and function of integrin α M β 2 (Mac-1) on neutrophil-derived microparticles. <i>Blood</i> , 2008, 112, 2327-2335.	0.6	174
822	Peroxisome proliferator-activated receptor α genetic variation interacts with ω 6 and long-chain ω 3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1926-1931.	2.2	48
823	Endothelial Domes Encapsulate Adherent Neutrophils and Minimize Increases in Vascular Permeability in Paracellular and Transcellular Emigration. <i>PLoS ONE</i> , 2008, 3, e1649.	1.1	96
824	The α x β 2 integrin CD11c is a potent costimulator of CD8 T cell responses. <i>FASEB Journal</i> , 2008, 22, 855.10.	0.2	0
825	Abstract 4985: Are All Patients Considered "Low Risk" for Coronary Heart Disease Really Low Risk? An Analysis from the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2008, 118, .	1.6	1
826	Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. <i>Texas Heart Institute Journal</i> , 2008, 35, 388-94.	0.1	6
827	Cardiometabolic Risk in Impaired Fasting Glucose and Impaired Glucose Tolerance: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2007, 30, 325-331.	4.3	81
828	A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Epidemiology</i> , 2007, 165, 1047-1054.	1.6	110

#	ARTICLE	IF	CITATIONS
829	An Annual, Prospective, International Study of Outpatients With Cardiovascular Disease or Risk Factors. <i>Critical Pathways in Cardiology</i> , 2007, 6, 72-75.	0.2	2
830	Increasing Prevalence of Obesity and Clustered Cardiometabolic Risk: Can Treatment of the Underlying Cause Reverse the Trends?. <i>Critical Pathways in Cardiology</i> , 2007, 6, 41-45.	0.2	5
831	Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , 2007, 29, 1354-1367.	1.1	371
832	L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. <i>Atherosclerosis</i> , 2007, 192, 56-66.	0.4	31
833	Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. <i>Atherosclerosis</i> , 2007, 193, 283-291.	0.4	32
834	Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. <i>Atherosclerosis</i> , 2007, 194, e131-e140.	0.4	60
835	T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity. <i>Circulation</i> , 2007, 115, 1029-1038.	1.6	577
836	A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. <i>EMBO Journal</i> , 2007, 26, 1129-1139.	3.5	344
837	Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). <i>American Journal of Cardiology</i> , 2007, 99, 673-680.	0.7	168
838	Biological Surrogates for Enhancing Cardiovascular Risk Prediction in Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 80-88.	0.7	45
839	Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels. <i>American Journal of Cardiology</i> , 2007, 99, 1706-1713.e1.	0.7	62
840	Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2007, 100, 1387-1396.	0.7	26
841	Treatment of Dyslipidemia to Reduce Cardiovascular Risk in Patients with Multiple Risk Factors. <i>Clinical Cornerstone</i> , 2007, 8, S6-S13.	1.0	16
842	Role of Biomarkers in Developing New Therapies for Vascular Disease. <i>World Journal of Surgery</i> , 2007, 31, 676-681.	0.8	14
843	Peripheral Arterial Occlusive Disease: Magnetic Resonance Imaging and the Role of Aggressive Medical Management. <i>World Journal of Surgery</i> , 2007, 31, 695-704.	0.8	21
844	Lipoprotein-associated phospholipase A2: Risk marker or target of therapy?. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 66-71.	0.8	0
845	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. , 2007, , 141-156.		0
846	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. <i>Journal of Experimental Medicine</i> , 2006, 203, 2569-2575.	4.2	599

#	ARTICLE	IF	CITATIONS
847	P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: The Atherosclerosis Risk In Communities Study. <i>Atherosclerosis</i> , 2006, 186, 74-79.	0.4	44
848	Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2504-H2514.	1.5	99
849	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY II). <i>American Heart Journal</i> , 2006, 151, 975.e1-975.e9.	1.2	87
850	Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. <i>Contemporary Clinical Trials</i> , 2006, 27, 518-530.	0.8	18
851	Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia. <i>Endocrine Practice</i> , 2006, 12, 159-164.	1.1	18
852	Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2006, 8, 374-381.	2.0	16
853	Application of Recent Definitions of the Metabolic Syndrome to Survey Data From the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 295-300.	1.7	2
854	Combination Therapy with Statins and Omega-3 Fatty Acids. <i>American Journal of Cardiology</i> , 2006, 98, 34-38.	0.7	71
855	Point: High-Sensitivity C-Reactive Protein and Cardiac C-Reactive Protein Assays: Is There a Need to Differentiate?. <i>Clinical Chemistry</i> , 2006, 52, 1254-1256.	1.5	11
856	Eotaxin and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 256-261.	1.8	109
857	Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants. <i>American Journal of Epidemiology</i> , 2006, 164, 342-348.	1.6	116
858	Adiposopathy: why do adiposity and obesity cause metabolic disease?. <i>Future Lipidology</i> , 2006, 1, 389-420.	0.5	60
859	The LFA-1 Adhesion Molecule Is Required for Protective Immunity during Pulmonary <i>Mycobacterium tuberculosis</i> Infection. <i>Journal of Immunology</i> , 2006, 176, 4914-4922.	0.4	48
860	An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers. <i>Archives of Internal Medicine</i> , 2006, 166, 1368.	4.3	323
861	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1556.	3.8	1,759
862	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006, 22, 2041-2053.	0.9	101
863	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. <i>Journal of Cell Biology</i> , 2006, 175, i13-i13.	2.3	0
864	Apolipoprotein E Genotype and Incident Ischemic Stroke. <i>Stroke</i> , 2005, 36, 2484-2486.	1.0	12

#	ARTICLE	IF	CITATIONS
865	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. <i>American Journal of Cardiology</i> , 2005, 95, 367-372.	0.7	43
866	Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations. <i>American Journal of Cardiology</i> , 2005, 96, 556-563.	0.7	257
867	Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction. <i>American Journal of Cardiology</i> , 2005, 96, 14-19.	0.7	15
868	Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus. <i>Clinical Cornerstone</i> , 2005, 7, 7-16.	1.0	31
869	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2005, 7, 22-28.	2.0	7
870	Comparison of the Instructional Efficacy of Internet-Based CME With Live Interactive CME Workshops. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1043.	3.8	335
871	A Comparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. <i>European Heart Journal</i> , 2005, 26, 2664-2672.	1.0	101
872	Identifying Individuals at High Risk for Diabetes: The Atherosclerosis Risk in Communities study. <i>Diabetes Care</i> , 2005, 28, 2013-2018.	4.3	401
873	PLAC ₂ test for identification of individuals at increased risk for coronary heart disease. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 9-14.	1.5	22
874	Manifestations of Inflammatory Arthritis Are Critically Dependent on LFA-1. <i>Journal of Immunology</i> , 2005, 174, 3668-3675.	0.4	84
875	The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2005, 28, 385-390.	4.3	988
876	Multiplexed Analysis of Biomarkers Related to Obesity and the Metabolic Syndrome in Human Plasma, Using the Luminex-100 System. <i>Clinical Chemistry</i> , 2005, 51, 1102-1109.	1.5	163
877	Fat, Fit, and Leading the Charge. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2013-2015.	1.1	4
878	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Archives of Internal Medicine</i> , 2005, 165, 2479.	4.3	244
879	Lipids and CVD management: towards a global consensus. <i>European Heart Journal</i> , 2005, 26, 2224-2231.	1.0	79
880	Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2005, 183, 301-307.	0.4	139
881	Markers of inflammation and their clinical significance. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-29.	1.2	125
882	Conditional Risk Factors for Atherosclerosis. <i>Mayo Clinic Proceedings</i> , 2005, 80, 219-230.	1.4	83

#	ARTICLE	IF	CITATIONS
883	Extra domain A and type III connecting segment of fibronectin in assembly and cleavage. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 1640-1647.	1.0	17
884	Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. <i>American Heart Journal</i> , 2005, 149, 464-473.	1.2	237
885	A Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1611-1619.	1.2	146
886	Cholesterol, lipids, and statins. <i>Texas Heart Institute Journal</i> , 2005, 32, 378-9.	0.1	6
887	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 3.	0.2	3
888	Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the atherosclerosis risk in communities (ARIC) Study. <i>Biomarkers</i> , 2004, 9, 190-202.	0.9	16
889	Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). <i>Diabetes Care</i> , 2004, 27, 1735-1740.	4.3	159
890	Measurement of Cholesterol. <i>Circulation</i> , 2004, 110, e296-7.	1.6	30
891	Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: The Impact of Rapid Weight Loss through Caloric Restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2697-2703.	1.8	255
892	Adiponectin and the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes</i> , 2004, 53, 2473-2478.	0.3	315
893	Deficiency of CD11b or CD11d Results in Reduced Staphylococcal Enterotoxin-Induced T Cell Response and T Cell Phenotypic Changes. <i>Journal of Immunology</i> , 2004, 173, 297-306.	0.4	77
894	Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study. <i>Diabetes Care</i> , 2004, 27, 77-82.	4.3	142
895	The Virulence Function of <i>Streptococcus pneumoniae</i> Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection. <i>Journal of Immunology</i> , 2004, 173, 7506-7512.	0.4	102
896	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2004, 109, 837-842.	1.6	598
897	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004, 93, 1487-1494.	0.7	184
898	Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004, 94, 795-797.	0.7	52
899	Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). <i>American Journal of Cardiology</i> , 2004, 94, 1249-1254.	0.7	156
900	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 67-75.	1.3	8

#	ARTICLE	IF	CITATIONS
901	Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. <i>Current Atherosclerosis Reports</i> , 2004, 6, 173-179.	2.0	18
902	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. <i>Current Atherosclerosis Reports</i> , 2004, 6, 353-358.	2.0	1
903	Endothelial lipase and cholesterol metabolism. <i>Current Atherosclerosis Reports</i> , 2004, 6, 126-130.	2.0	12
904	Role of selective cholesterol absorption inhibition in the management of dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2004, 6, 52-59.	2.0	7
905	Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. <i>Magnetic Resonance Imaging</i> , 2004, 22, 1249-1258.	1.0	55
906	Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. <i>Pharmacoeconomics</i> , 2004, 22, 13-23.	1.7	104
907	Management of metabolic syndrome: statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 509-523.	1.2	7
908	Fluvastatin. <i>Drugs</i> , 2004, 64, 1305-1323.	4.9	23
909	Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. <i>Clinical Therapeutics</i> , 2004, 26, 1855-1864.	1.1	27
910	Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Fas ^{lpr} Mice from Autoimmune Disease. <i>American Journal of Pathology</i> , 2004, 165, 609-616.	1.9	78
911	Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. <i>American Heart Journal</i> , 2004, 148, S3-S8.	1.2	14
912	Effects of PPAR α , β and γ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 61-71.	5.7	50
913	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. <i>Journal of Clinical Investigation</i> , 2004, 114, 408-418.	3.9	81
914	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. <i>Journal of Clinical Investigation</i> , 2004, 114, 408-418.	3.9	65
915	Gender-Dependent Up-Regulation of the VWF-Cleaving metalloprotease ADAMTS-13 in Mice with Obesity and Hypercholesterolemia. <i>Blood</i> , 2004, 104, 3500-3500.	0.6	0
916	Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. <i>American Journal of Cardiology</i> , 2003, 91, 33-41.	0.7	131
917	Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2003, 91, 25-27.	0.7	38
918	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2003, 91, 1134-1136.	0.7	6

#	ARTICLE	IF	CITATIONS
919	Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacy and safety. <i>American Journal of Cardiology</i> , 2003, 92, 3-9.	0.7	105
920	B vitamin status and inflammatory markers. <i>Atherosclerosis</i> , 2003, 169, 169-174.	0.4	57
921	Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with Î±IIbÎ³3 and Î±MÎ²2, in coronary stenting. <i>Thrombosis Research</i> , 2003, 111, 171-177.	0.8	47
922	Role of lipid and lipoprotein profiles in risk assessment and therapy. <i>American Heart Journal</i> , 2003, 146, 227-233.	1.2	56
923	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHES). <i>American Heart Journal</i> , 2003, 146, 862-869.	1.2	69
924	Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. <i>Circulation</i> , 2003, 107, 2409-2415.	1.6	627
925	Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. <i>Atherosclerosis</i> , 2003, 171, 265-272.	0.4	60
926	Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. <i>Clinical Therapeutics</i> , 2003, 25, 1670-1686.	1.1	40
927	From Vulnerable Plaque to Vulnerable Patient. <i>Circulation</i> , 2003, 108, 1664-1672.	1.6	2,308
928	From Vulnerable Plaque to Vulnerable Patient. <i>Circulation</i> , 2003, 108, 1772-1778.	1.6	1,562
929	Risk for Myopathy With Statin Therapy in High-Risk Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 553.	4.3	404
930	Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease. <i>Circulation</i> , 2003, 107, 1729-1732.	1.6	54
931	Long-Term, Randomized Clinical Trial of Two Diets in the Metabolic Syndrome and Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 2481-2482.	4.3	36
932	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription. <i>Circulation</i> , 2003, 107, 2102-2108.	1.6	147
933	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2748-2753.	3.3	218
934	Detection of Undiagnosed Diabetes and Other Hyperglycemia States: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2003, 26, 1338-1343.	4.3	36
935	Host Resistance of CD18 Knockout Mice against Systemic Infection with <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2003, 71, 5986-5993.	1.0	17
936	Mac-1, but Not LFA-1, Uses Intercellular Adhesion Molecule-1 to Mediate Slow Leukocyte Rolling in TNF-Î±-Induced Inflammation. <i>Journal of Immunology</i> , 2003, 171, 6105-6111.	0.4	113

#	ARTICLE	IF	CITATIONS
937	Low-Grade Systemic Inflammation and the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes</i> , 2003, 52, 1799-1805.	0.3	908
938	Plasma Lipid Profile and Incident Ischemic Stroke. <i>Stroke</i> , 2003, 34, 623-631.	1.0	279
939	Role of non-HDL high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. <i>Current Opinion in Cardiology</i> , 2003, 18, 503-509.	0.8	20
940	Roles of neutrophil β_2 integrins in kinetics of bacteremia, extravasation, and tick acquisition of <i>Anaplasma phagocytophila</i> in mice. <i>Blood</i> , 2003, 101, 3257-3264.	0.6	19
941	Unanswered questions about the use of statins. , 2003, , 228-240.		0
942	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. <i>Journal of Lipid Research</i> , 2002, 43, 1170-1180.	2.0	253
943	Soluble Adhesion Molecules and the Search for Biomarkers for Atherosclerosis. <i>Circulation</i> , 2002, 106, 766-767.	1.6	61
944	Role of β_4 Integrin and VCAM-1 in CD18-Independent Neutrophil Migration Across Mouse Cardiac Endothelium. <i>Circulation Research</i> , 2002, 90, 562-569.	2.0	98
945	Control of leukocyte rolling velocity in TNF- α -induced inflammation by LFA-1 and Mac-1. <i>Blood</i> , 2002, 99, 336-341.	0.6	180
946	Soluble adhesion molecules and coronary heart disease. <i>Lancet</i> , The, 2002, 359, 525.	6.3	5
947	Cardiovascular risk factors associated with immunosuppression in renal transplantation. <i>Transplantation Reviews</i> , 2002, 16, 1-21.	1.2	18
948	Use of Denaturing HPLC to Provide Efficient Detection of Mutations Causing Familial Hypercholesterolemia. <i>Clinical Chemistry</i> , 2002, 48, 1913-1918.	1.5	29
949	Combination therapy for combined dyslipidemia. <i>American Journal of Cardiology</i> , 2002, 90, 21-29.	0.7	53
950	LPL polymorphism predicts stroke risk in men. <i>Genetic Epidemiology</i> , 2002, 22, 233-242.	0.6	42
951	Statins and inflammatory markers. <i>Current Atherosclerosis Reports</i> , 2002, 4, 42-47.	2.0	20
952	Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. <i>Journal of Molecular Medicine</i> , 2002, 80, 737-744.	1.7	42
953	Kinetics of CD11b/CD18 Up-Regulation During Infection with the Agent of Human Granulocytic Ehrlichiosis in Mice. <i>Laboratory Investigation</i> , 2002, 82, 303-311.	1.7	31
954	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. <i>Journal of Lipid Research</i> , 2002, 43, 1170-80.	2.0	102

#	ARTICLE	IF	CITATIONS
955	Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. <i>Clinical Chemistry</i> , 2002, 48, 1913-8.	1.5	6
956	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. <i>Atherosclerosis</i> , 2001, 154, 633-640.	0.4	55
957	The Evolving Role of High-Density Lipoprotein in Reducing Cardiovascular Risk. <i>Preventive Cardiology</i> , 2001, 4, 65-72.	1.1	3
958	Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. <i>American Journal of Medicine</i> , 2001, 111, 185-191.	0.6	166
959	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. <i>Clinical Therapeutics</i> , 2001, 23, 177-192.	1.1	71
960	Treating mixed dyslipidemias: Why and how. <i>Clinical Cardiology</i> , 2001, 24, 6-9.	0.7	11
961	Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. <i>American Journal of Cardiology</i> , 2001, 88, 265-269.	0.7	157
962	The Differential Roles of LFA-1 and Mac-1 in Host Defense Against Systemic Infection with <i>Streptococcus pneumoniae</i> . <i>Journal of Immunology</i> , 2001, 166, 7362-7369.	0.4	78
963	In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease. <i>Circulation</i> , 2001, 103, 2768-2770.	1.6	76
964	Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy. <i>Circulation Research</i> , 2001, 88, 969-973.	2.0	104
965	Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S. <i>Circulation</i> , 2001, 104, 3046-3051.	1.6	390
966	Newer risk markers and surrogate endpoints in atherosclerosis management. <i>Clinical Cardiology</i> , 2001, 24, 13-17.	0.7	4
967	EFFECT OF SIROLIMUS ON THE METABOLISM OF ApoB100- CONTAINING LIPOPROTEINS IN RENAL TRANSPLANT PATIENTS1. <i>Transplantation</i> , 2001, 72, 1244-1250.	0.5	114
968	Plasma Lipids, Lipoproteins, and Apolipoproteins and Incident Ischemic Stroke. <i>Circulation</i> , 2001, 103, 1363-1363.	1.6	0
969	Mechanism of chronic obstructive uropathy: Increased expression of apoptosis-promoting molecules. <i>Kidney International</i> , 2000, 58, 1481-1491.	2.6	65
970	Introduction. <i>American Journal of Cardiology</i> , 2000, 85, 1-2.	0.7	1
971	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. <i>American Journal of Cardiology</i> , 2000, 85, 30-35.	0.7	25
972	Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. <i>American Journal of Cardiology</i> , 2000, 86, 759-763.	0.7	26

#	ARTICLE	IF	CITATIONS
973	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. <i>Current Atherosclerosis Reports</i> , 2000, 2, 281-283.	2.0	0
974	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. <i>Journal of Molecular Medicine</i> , 2000, 78, 562-568.	1.7	34
975	Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H835-H842.	1.5	16
976	A Variant of p22 ^{phox} , Involved in Generation of Reactive Oxygen Species in the Vessel Wall, Is Associated With Progression of Coronary Atherosclerosis. <i>Circulation Research</i> , 2000, 86, 391-395.	2.0	134
977	Platelet Glycoprotein Ib α Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18). <i>Journal of Experimental Medicine</i> , 2000, 192, 193-204.	4.2	558
978	Primary Prevention of Coronary Heart Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2089-2092.	1.8	63
979	Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data. <i>Archives of Internal Medicine</i> , 2000, 160, 1361.	4.3	70
980	IL-10 Is Induced in the Reperfused Myocardium and May Modulate the Reaction to Injury. <i>Journal of Immunology</i> , 2000, 165, 2798-2808.	0.4	261
981	Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. <i>Journal of the American College of Cardiology</i> , 2000, 35, 89-95.	1.2	77
982	Statins after cardiac transplantation: which statin, what dose, and how low should we go?. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 515-517.	0.3	22
983	Apolipoprotein E genotypes and response of plasma lipids and progression of coronary atherosclerosis to lipid-lowering drug therapy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1572-1578.	1.2	91
984	Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. <i>Journal of Lipid Research</i> , 2000, 41, 1060-1066.	2.0	31
985	Decreased neointimal formation in Mac-1 ^{-/-} mice reveals a role for inflammation in vascular repair after angioplasty. <i>Journal of Clinical Investigation</i> , 2000, 105, 293-300.	3.9	213
986	Myocardial infarction and remodeling in mice: effect of reperfusion. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 277, H660-H668.	1.5	76
987	Effect of Moderate Alcohol Consumption on Hypertriglyceridemia. <i>Archives of Internal Medicine</i> , 1999, 159, 981.	4.3	58
988	Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy. <i>Circulation</i> , 1999, 99, 736-743.	1.6	191
989	Adhesion molecules in cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 263-277.	1.0	3
990	Reducing atherothrombotic events in high-risk patients: Recent data on therapy with statins and fatty acids. <i>Current Atherosclerosis Reports</i> , 1999, 1, 6-8.	2.0	4

#	ARTICLE	IF	CITATIONS
991	Inflammation and lipid-lowering treatment. <i>Current Cardiology Reports</i> , 1999, 1, 251-255.	1.3	1
992	Correlation of serum triglyceride and its reduction by ω -3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. <i>Atherosclerosis</i> , 1999, 143, 285-297.	0.4	161
993	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. <i>Atherosclerosis</i> , 1999, 144, 435-442.	0.4	35
994	Clinical trial endpoints: angiograms, events, and plaque instability. <i>American Journal of Cardiology</i> , 1998, 82, 5M-11M.	0.7	54
995	Low-density lipoproteins and risk for coronary artery disease. <i>American Journal of Cardiology</i> , 1998, 82, 3-12.	0.7	303
996	Cytokines and the Microcirculation in Ischemia and Reperfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 1998, 30, 2567-2576.	0.9	168
997	Current thinking in lipid lowering. <i>American Journal of Medicine</i> , 1998, 104, 33S-41S.	0.6	23
998	Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 723-731.	1.1	196
999	Stem Cell Factor Induction Is Associated With Mast Cell Accumulation After Canine Myocardial Ischemia and Reperfusion. <i>Circulation</i> , 1998, 98, 687-698.	1.6	170
1000	Maximizing the Cost-effectiveness of Lipid-Lowering Therapy. <i>Archives of Internal Medicine</i> , 1998, 158, 1977.	4.3	69
1001	Pathophysiology of Atherosclerosis. <i>Developments in Cardiovascular Medicine</i> , 1998, , 3-58.	0.1	0
1002	Dyslipidemia, Diabetes, and Cell Adhesion Molecules. <i>Medical Science Symposia Series</i> , 1998, , 191-198.	0.0	0
1003	Effects of lipid lowering therapy on progression of coronary and carotid artery disease. <i>Current Opinion in Lipidology</i> , 1997, 8, 354-361.	1.2	48
1004	Pathophysiology and treatment of lipid perturbation after cardiac transplantation. <i>Current Opinion in Cardiology</i> , 1997, 12, 153-160.	0.8	17
1005	Molecular markers for atherosclerosis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1997, 4, 353-356.	1.5	6
1006	Phagocytes in Ischemia Injury. <i>Annals of the New York Academy of Sciences</i> , 1997, 832, 243-265.	1.8	9
1007	Effects of Fluvastatin on Coronary Atherosclerosis in Patients With Mild to Moderate Cholesterol Elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). <i>American Journal of Cardiology</i> , 1997, 80, 278-286.	0.7	317
1008	Induction of Monocyte Chemoattractant Protein-1 in the Small Veins of the Ischemic and Reperfused Canine Myocardium. <i>Circulation</i> , 1997, 95, 693-700.	1.6	147

#	ARTICLE	IF	CITATIONS
1009	Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases. <i>Circulation</i> , 1997, 96, 4219-4225.	1.6	1,133
1010	Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. <i>American Journal of Cardiology</i> , 1996, 78, 532-535.	0.7	18
1011	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. <i>Medical Science Symposia Series</i> , 1996, , 675-680.	0.0	1
1012	Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia. <i>Circulation</i> , 1996, 93, 1334-1338.	1.6	256
1013	Association of Neutrophils With Platelet Aggregates in Unstable Angina. <i>Circulation</i> , 1996, 94, 1206-1208.	1.6	26
1014	Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. <i>Molecular and Cellular Biochemistry</i> , 1995, 147, 5-12.	1.4	63
1015	Cloning and comparative sequence analysis of the gene encoding canine intercellular adhesion molecule-1 (ICAM-1). <i>Gene</i> , 1995, 156, 291-295.	1.0	12
1016	Cardiac Allograft Survival in Mice Deficient in Intercellular Adhesion Molecule-1. <i>Circulation</i> , 1995, 92, 82-87.	1.6	42
1017	Baseline characteristics of subjects in the lipoprotein and coronary atherosclerosis study (LCAS) with fluvastatin. <i>American Journal of Cardiology</i> , 1994, 73, D42-D49.	0.7	17
1018	Regulation of ICAM-1 and IL-6 in Myocardial Ischemia: Effect of Reperfusion a. <i>Annals of the New York Academy of Sciences</i> , 1994, 723, 258-270.	1.8	55
1019	Increases in Lung Tissue Expression of Intercellular Adhesion Molecule-1 Are Associated with Hyperoxic Lung Injury and Inflammation in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1993, 9, 393-400.	1.4	62
1020	Characterization of the murine Icam-1 gene. <i>Genomics</i> , 1992, 14, 1076-1080.	1.3	36
1021	Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. <i>Journal of the American College of Cardiology</i> , 1992, 19, 1315-1321.	1.2	125
1022	Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. <i>Journal of the American College of Cardiology</i> , 1991, 18, 926-930.	1.2	43
1023	Assignment of the gene for intercellular adhesion molecule-1 (Icam-1) to proximal mouse chromosome 9. <i>Genomics</i> , 1991, 9, 547-550.	1.3	21
1024	Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. <i>American Journal of Cardiology</i> , 1991, 67, 243-247.	0.7	191
1025	Nucleotide sequence of the cDNA for murine intercellular adhesion molecule-1 (ICAM-1). <i>Nucleic Acids Research</i> , 1989, 17, 5853-5853.	6.5	43
1026	Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels. <i>JAMA - Journal of the American Medical Association</i> , 1989, 262, 53.	3.8	205

#	ARTICLE	IF	CITATIONS
1027	Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 270-276.	1.5	31
1028	Newer Markers for Population Screening: Focus on Lipoprotein-Related Markers. , 0, , 181-203.		0